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Abstract 
 
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central 
nervous system (CNS), which results in a wide range of neurological disabilities. 
Etiological studies have implicated environmental and genetic factors in causing 
increased disease susceptibility. Yet, the cause of MS remains unknown, and the 
mechanisms that promote the disease are poorly understood. The pathophysiology that 
promotes the disease is hypothesized to be an immune reaction mediated by pro-
inflammatory T cells reactive against CNS derived self-antigens. Interestingly, regulatory 
T cells (Tregs), protectors against such autoimmune responses, are defective in MS 
patients.  While genetic studies have implicated variants of immune-related genes in 
disease susceptibility, these variants only account for approximately 20-60% of the 
genetic contributors to the disease. Therefore, a tremendous need remains for the 
identification of additional genetic and susceptibility factors. 
 
To this end, our lab has been investigating microRNAs (miRNAs) in the context of MS. 
miRNAs regulate gene expression and thus, modify cellular pathways and disease 
processes. In addition to being biological regulators, miRNAs are easily quantifiable in 
cells, tissue, and bodily fluids, making them attractive candidates for potential markers of 
MS pathogenesis. The lab previously performed a miRNA profiling study on the naïve 
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CD4 T cells of MS patients and healthy donors, and identified 85 differentially expressed 
miRNAs. Pathway analysis predicted 19 of the 85 miRNAS to target and inhibit the 
TGFβ signaling pathway. TGFβ is a pleiotropic cytokine critical for the development and 
function of Tregs. Given the importance of TGFβ in regards to Tregs, we hypothesized 
that dysregulated miRNAs in the naïve CD4+ T cells of MS patients inhibit the TGFβ-
signaling pathway, resulting in defective Tregs and enhanced susceptibility to developing 
MS.  
 
Our data indicate that 1) TGFβ-signaling genes are decreased in MS patients, 2) miRNAs 
when overexpressed negatively regulate the TGFβ signaling pathway and reduce the 
capacity for Treg differentiation from naïve CD4 T cells, and 3) overexpression of 
miRNAs, in the context of experimental autoimmune encephalomyelitis, promote earlier 
onset and increased severity of disease. Taken together, our data indicate that the 
dysregulation of TGFβ-targeting miRNAs in naïve CD4 T cells of MS patients can 
inhibit TGFβ signaling, dampen Treg development, and promote CNS autoimmunity. 
Therefore, these miRNAs are potential candidates for markers of disease susceptibility 
and therapeutic targets.  
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Chapter 1:  Introduction 
 
Introduction 
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central 
nervous system (CNS) that devastatingly affects approximately 2.5 million people 
worldwide (Hersh and Fox 2010). While the patholophysiology of the disease has not 
been completely uncovered, it has been characterized by inflammation, demyelination, 
and neurodegeneration, resulting in a wide range of neurologic symptoms. Unfortunately, 
MS is the leading cause of non-traumatic disability in young adults. Given the 
unpredictable and progressive nature of the disease, diagnosis with MS can greatly 
impact a patient's quality of life from an early age, putting their autonomy at risk. 
Currently, there is no cure for MS and available treatments are limited. Despite the ability 
of existing therapies to slow down disease progression, the eventual accumulation of 
symptoms is inevitable. Identification of individuals susceptible to developing MS may 
allow these patients to be proactive by submitting to routine screening and to prepare 
themselves for possible diagnosis. Efforts to identify factors for disease susceptibility 
have uncovered gender, geographical, and genetic biases. Yet, the etiology of MS is 
unknown and there remains no cure. Additionally, mechanisms that promote disease 
pathology are not well understood. This lack of knowledge has made preventing MS 
impossible and halting disease progression challenging. Therefore, research aimed at the 
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identification of novel biomarkers and therapeutic targets is critical for understanding 
disease activity, measuring treatment efficacy, and stopping disease progression. In order 
to move forward in research, it is important to first take into account the studies that serve 
as the foundation for modern research. The first attempts at understanding and treating 
MS can be dated back to the 19
th 
century. 
 
Multiple Sclerosis (MS) 
In 1837, Robert Carswell, a Scottish pathologist, published his illustrations of lesions in 
the brain and spinal cords of patients post mortem in Illustrations of the Elementary 
Forms of Disease. While his findings predate the naming of MS and the invention of 
magnetic resonance imaging (MRI), his 19
th
 century depictions of the disease provided a 
basis for understanding its pathogenesis and the importance of lesion formation. It was 
not until 1868 that MS was first described by Jean-Martin Charcot, a French neurologist, 
as ‘ la sclerosé en plaques,’ thus naming the disease and distinguishing MS from other 
known neurological ailments of the time (Charcot 1868). Charcot was the first to 
summarize clinical reports on MS patients and identify symptoms such as ‘nystagmus, 
intention tremor, and scanning speech,’ now known as Charcot’s neurological triad 
(Charcot 1868, Murray 2005). While Carswell and Charcot’s observations are not 
exclusive to MS, these findings built the foundation for modern use of the presence of 
CNS lesions and neurological symptoms in the diagnosis of MS patients. 
 
3 
 
Currently, 2.5 million people have been diagnosed with MS worldwide, with over 
450,000 patients in the United States alone (Hersh and Fox 2010). Unfortunately, MS is 
the leading cause of non-traumatic disability in young adults, with diagnosis typically 
occurring between the ages of 20-40 (Hersh and Fox 2010).  MS patients suffer from a 
wide range of neurological symptoms, including but not limited to pain, coordination 
impairment, cognitive changes, and emotional distress. The first episode of neurological 
symptoms experienced by a patient is known as a clinically isolated syndrome (CIS). 
Individuals that present with a CIS may or may not go on to develop clinically definite 
MS (CDMS). Standard methods for diagnosis include medical history, neurological 
examination, MRI, and other secondary tests, such as analysis of cerebrospinal fluid 
(CSF) (McDonald, Compston et al. 2001, Filippi, Dousset et al. 2002, Polman, Reingold 
et al. 2011, Gelfand 2014). In order for a patient to have CDMS, revised diagnostic 
criteria require that a patient demonstrates CNS specific inflammatory demyelinating 
lesions that are disseminated in both space and time (Polman, Reingold et al. 2011).  
 
CNS lesions are typically detected by either T1-weighted gadolinium enhancing or T2-
weighted MRI scans and can provide useful knowledge about the disease state. T2 lesions 
are representative of total lesion load, both old and new, whereas T1 lesions are more 
specific. Under normal conditions, gadolinium is a large dye incapable of penetrating the 
blood brain barrier (BBB); as such, detection of gadolinium-enhanced T1 lesions in the 
brain is indicative of newly formed or expanding areas of inflammation. The 
inflammation observed in these lesions can cause damage to the myelin sheath and 
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ultimately the impairment of nerve signal transduction. Symptoms are determined by the 
spinal or cerebral location of the lesions, and severity of the symptoms correlates with the 
amount of axonal damage (Trapp, Peterson et al. 1998, Charil, Dagher et al. 2007, Charil 
and Filippi 2007, Frischer, Bramow et al. 2009). While remyelination of axons can 
initially occur, leading to functional recovery, damage eventually accumulates, resulting 
in neurodegeneration and permanent neurological deficits. Periods of inflammatory 
attacks and symptom worsening are called relapses, where as the periods between 
exacerbations are called remissions.  
 
Based on patterns of relapses and remissions, MS patients can be separated into three 
main categories, relapsing-remitting (RRMS), secondary-progressive (SPMS), and 
primary progressive (PPMS). PPMS is the most rare form of the three categories, 
occurring in only 10-15% of patients, and is characterized by steady worsening of disease 
from the time of onset without remission. RRMS is the most common form of MS and is 
defined by acute attacks of inflammation resulting in relapses followed by complete or 
incomplete remissions. This phase is followed by SPMS, which is defined by a steady 
worsening in disease, potentially with brief incomplete remissions. Of the 85% of people 
initially diagnosed with RRMS, almost all eventually advance to the progressive phase of 
the disease. Given the unpredictable and progressive nature of the disease, diagnosis with 
MS can greatly affect a patient's quality of life from an early age. Both relapses and 
progression occur spontaneously, forcing patients to live a life full of fluctuating function 
and uncertainty. Currently, there is no cure for MS. Available treatments are limited, with 
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only one treatment available for SPMS and none available for PPMS. Studies have 
demonstrated that early use of therapies in patients presenting with a CIS have a delayed 
conversion to CDMS (Jacobs, Beck et al. 2000, Comi, Filippi et al. 2001, Kappos, 
Polman et al. 2006, Comi, Martinelli et al. 2009, Miller, Wolinsky et al. 2014). 
Therefore, diagnosis of patients early during the disease process while treatments are 
available is essential for delaying progression of the disease. However, diagnosis is 
challenging, as there is no single test for MS and the cause is unknown. Therefore, 
understanding the mechanisms that underline disease susceptibility and activity is 
necessary for identifying novel therapeutic targets, stopping disease progression, and 
potentially preventing disease all together. To this end, numerous studies have attempted 
to uncover the main contributors to the disease; initial research focused primarily on 
widespread epidemiologic and genetic analyses of MS patients. 
 
Epidemiological studies analyzing the familial, geographic, and gender distribution of 
MS have indicated that there are both genetic and environmental components to disease 
susceptibility. Familial studies have established  ~25% concordance between 
monozygotic twins and ~5% concordance among dizygotic twins, demonstrating that MS 
has incomplete penetrance (Mackay and Myrianthopoulos 1966, Ebers, Bulman et al. 
1986, Willer, Dyment et al. 2003). Therefore, genetic predisposition only partially 
explains MS etiology. In the past 30 years, variations within the human leukocyte antigen 
(HLA) class II locus have been most frequently identified as MS associated risk alleles 
(Haegert and Marrosu 1994). However, HLA associated risk only accounts for 
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approximately 20-60% of genetic susceptibility for MS (Haines, Terwedow et al. 1998). 
In addition to classic HLA risk alleles, genome-wide association studies (GWAS) have 
identified variants of immune-related alleles, such as interleukin 2 receptor alpha chain 
(IL-2R) and interleukin 7 receptor alpha chain (IL-7R), as potential risk factors 
(Baranzini, Galwey et al. 2009, De Jager, Jia et al. 2009, Beecham, Patsopoulos et al. 
2013). Importantly, genetic studies have implicated genes of the immune system as being 
important in MS, providing insight into the pathogenesis of the disease. However, these 
studies have had limited success in identifying genetic markers with high sensitivity. 
Taken together, these data suggest MS is multi-factorial and not solely influenced by 
genetic factors. 
 
Historically, population studies have shown that MS is more frequently observed in post-
pubescent individuals (Chitnis 2013), women (Greer and McCombe 2011, Wallin, 
Culpepper et al. 2012), Caucasians of European decent (Kurtzke, Beebe et al. 1979, 
Rosati 2001), and in areas farthest from the equator. However, newer studies 
demonstrating a shift in ethnic bias indicate that individuals of African descent have 
equal incidence of MS compared to Caucasians, which has been attributed to darker skin 
tones limiting sunlight uptake (Kurland and Reed 1964, Evans, Beland et al. 2013, 
Langer-Gould, Brara et al. 2013). Additionally, the bias based on latitudinal location also 
suggests that sunlight (Simpson, Blizzard et al. 2011), in addition to other environmental 
factors such as pathogen exposure (Gale and Martyn 1995), may be important. Migration 
studies analyzing the effects of changes in latitudinal location indicate that the effect of 
7 
 
relocation on disease predisposition is age dependent (Alter, Leibowitz et al. 1966, Dean 
1967, Dean and Elian 1997). Individuals that move as children assume the susceptibility 
of their adopted country; whereas adults that migrate retained the susceptibility rate of 
their native country. These findings suggest that exposure to certain environmental 
stimuli during childhood, a period critical in the development of the immune system, can 
affect an individual’s predisposition to developing MS. Understanding how these stimuli 
potentiate their effects could provide valuable insight into the immune mechanisms 
underlying the initiation of MS, which in turn would further the investigation for 
preventative and therapeutic treatments for the disease. 
 
Currently, there are two popular hypotheses for how exposure to infectious agents in the 
environment can inadvertently trigger the immune responses observed in MS. The first 
hypothesis, molecular mimicry, suggests that pathogens have antigenic elements that 
mimic CNS antigens and can cross react with autoreactive T cells. The alternative 
hypothesis, bystander effect, proposes that during the normal course of clearing an 
infection there is non-specific activation of autoreactive T cells. Both of these hypotheses 
implicate pathogens as being the initiating triggers in susceptible individuals. For 
instance, viruses such as Epstein-Barr virus (Handel, Williamson et al. 2010) and human 
herpes virus 6 (Chapenko, Millers et al. 2003) have been associated with MS, but none 
have been proven to be causal agents of the disease. While etiologic studies have 
identified some potential contributing factors of MS, there is tremendous need for 
understanding how and where disease is initiated. An ongoing question in MS is whether 
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inflammatory events in the periphery or neurodegenerative events in the CNS drive the 
initiation of this indisputably immune-mediated disease. Two primary hypotheses, 
outside-in and inside-out, have been posed to address this question (Stys, Zamponi et al. 
2012). The outside-in hypothesis suggests that an immune-activating event, such as 
molecular mimicry and bystander activation, occurs in the periphery that leads to 
immune-targeting of the CNS. Evidence supporting this hypothesis has demonstrated the 
association of immune-related genes and mechanisms with MS (Sawcer, Hellenthal et al. 
2011). Recently, an alternative hypothesis has been proposed, based on clinical 
observations, that suggests a primary neurodegenerative event in the CNS releases myelin 
antigens, resulting in activation of the immune system and a secondary autoimmune 
response (Hauser and Oksenberg 2006, Trapp and Nave 2008, Dutta and Trapp 2011). 
Further investigation of these hypotheses is crucial, as elucidating the mechanisms that 
drive MS is essential for identifying therapeutic targets that can modulate early in 
disease. However, the anatomical location of MS makes in-depth investigation of patients 
challenging, highlighting the importance of an in vivo model. The animal model known 
as experimental autoimmune encephalomyelitis (EAE) has been crucial in dissecting the 
components that contribute to various stages in CNS autoimmunity. 
 
Experimental Autoimmune Encephalomyelitis (EAE) 
The development of EAE, previously called experimental allergic encephalomyelitis, as a 
model for MS was pivotal in providing a controlled method for identifying in vivo 
mechanisms of CNS demyelination and autoimmunity.The  EAE model was initially 
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developed by Rivers, Sprunt, and Berry in 1933, in an attempt to understand why some 
individuals develop post-rabies vaccination encephalomyelitis (Rivers, Sprunt et al. 1933, 
Rivers and Schwentker 1935). Monkeys that received repeated intramuscular injections 
of aqueous emulsion and rabbit brain extracts, experienced paralysis caused by CNS 
lesions (Rivers and Schwentker 1935). EAE has many similarities to MS, such as the 
presence of inflammatory lesions. Over the past 40 years, various EAE models have been 
developed, each mimicking specific components of MS pathogenesis. When EAE models 
are correctly applied, they can be useful tools for identifying immune components and 
testing MS therapeutics.  
 
Active and passive inductions are the two widely accepted methods for producing EAE in 
mice. Active induction of EAE involves the immunization of rodents with CNS-specific 
immunogens, such as myelin oligodendrocyte glycoprotein (MOG) or myelin basic 
protein (MBP), emulsified in complete Freund’s adjuvant (CFA), resulting in the 
initiation of an immune response against self-antigens found in the brain and spinal cord 
(Stromnes and Goverman 2006). Actively inducing disease drives an immune response 
directed against the CNS, but it also allows for antigen presenting cells (APCs) to 
naturally process antigen, present peptides, and activate T cells in vivo. In contrast, 
passive EAE involves adoptively transferring activated T cells reactive to myelin 
antigens into naïve recipient animals (Stromnes and Goverman 2006). Passively 
transferring EAE provides a useful method for dissecting out the role of immune cells 
subsets critical for EAE by allowing the cells to be manipulated prior to being 
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transferred. For instance, cells can be sorted and labeled as a means of tracking migration 
of these cells in vivo. Active and passive EAE have both been fundamental in 
determining the importance and specific role of individual cell subsets important for the 
development and progression of EAE and MS. 
 
Immune Responses in EAE and MS 
Since 1960, myelin-specific B and T cells have been identified as contributors to the CNS 
damage observed in EAE (Paterson 1960, Pettinelli and McFarlin 1981, Sriram, Solomon 
et al. 1982, Fillatreau, Sweenie et al. 2002).  Philip Paterson was the first person to show 
that the passive transfer of lymphocytes from spinal cord sensitized animals induces EAE 
in naïve recipients (Paterson 1960). Using this model on T cell-depleted animals clearly 
established the specific requirement for thymus-derived lymphocytes in the initiation of 
EAE.  Further studies demonstrated that the transfer of myelin-reactive T helper (Th) 
cells, specifically, induces EAE, whereas exclusion of Th cells can prevent disease 
initiation (Ben-Nun, Wekerle et al. 1981, Ben-Nun, Wekerle et al. 1981, Ben-Nun and 
Cohen 1982, Ben-Nun and Lando 1983, Mokhtarian, McFarlin et al. 1984). These and 
other studies led to the conclusion that EAE is a major histocompatability complex 
(MHC) class-II restricted T cell-mediated disease (Sriram and Steinman 1983, Steinman, 
Solomon et al. 1983, Waldor, Sriram et al. 1983, Zamvil, Mitchell et al. 1987). When 
EAE lesions were examined, both CD8 and CD4 cells were observed in the cellular 
infiltrate. Interestingly, peripheral myelin-specific T cells were detected in both diseased 
and naïve animals (Schluesener and Wekerle 1985, Zamvil, Mitchell et al. 1987, Genain, 
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Lee-Parritz et al. 1994). These findings among those of others demonstrated a role for T 
cells as mediators of CNS inflammation and drove researchers to investigate the 
pathogenic properties of T cell subsets in the context of MS.  
 
Given the localization of the affected organ system and standard challenges with human 
research, the role of T cells in MS pathogenesis has not easily been elucidated. 
However, evidence suggests that MS patients share, in part, similar T cell characteristics 
and roles in driving CNS inflammation. One of the characterizing features of MS is the 
presence of perivascular cellular infiltrates primarily composed of T cells and 
macrophages (Frohman, Racke et al. 2006). MS patients also have CNS-specific 
autoreactive T cells in their periphery, but as seen in mice, these cells are also present in 
healthy individuals. However, characteristics of these autoreactive cells vary greatly, as 
determined by studies comparing the phenotype, reactivity, and diversity of the myelin-
specific T cells from MS patients and healthy individuals (Sun, Olsson et al. 1991, 
Lovett-Racke, Trotter et al. 1998, Pelfrey, Rudick et al. 2000, Crawford, Yan et al. 
2004).  In terms of T cell receptor (TCR) diversity, the CD4 T cells of MS patients 
recognize more myelin-specific epitopes than healthy individuals, a potential 
consequence of epitope spreading (Pelfrey, Rudick et al. 2000, Crawford, Yan et al. 
2004). MS patients have CD4 T cells with predominately activated/memory phenotypes, 
and display a higher magnitude of Th1 committed cells and IFNɣ production (Lovett-
Racke, Trotter et al. 1998, Scholz, Patton et al. 1998, Pelfrey, Rudick et al. 2000). These 
autoreactive T cells are thought to infiltrate the BBB, gain access to the CNS, and secrete 
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cytokines and chemokines in order to attract other immune cells and promote myelin 
damage.  These findings demonstrate that CD4 T cells are, at least in part, facilitating 
CNS inflammation, supporting observations made in EAE. When taken together, 
evidence from MS patients and animals with EAE indicate an apparent lack in regulation 
of T cell function and antigen recognition. 
 
Regulatory T Cells (Tregs) 
One of the main elements of regulation that is lacking in MS patients is a fully 
functional regulatory T cell (Treg) population. Under normal conditions, Tregs are 
essential for negatively regulating the immune system by maintaining immune 
homeostasis and self-tolerance (Sakaguchi, Sakaguchi et al. 1995, Sakaguchi, Sakaguchi 
et al. 2001, Shevach, McHugh et al. 2001). Tregs can be separated into two main 
categories based on their mechanism and location of origin: natural Tregs (nTregs) and 
inducible Tregs (iTregs).  Starting in 1969, predating the naming of nTregs, T cell 
depletion studies observed multi-organ autoimmune disease in neonatal mice that 
received thymectomies 2-3 days after birth, demonstrating for the first time the 
importance of thymic derived T cells in establishing self tolerance (Nishizuka and 
Sakakura 1969, Penhale, Farmer et al. 1973, Kojima and Prehn 1981). Similar 
observations of autoimmunity were made in rodents following adult thymectomies with 
subsequent rounds of irradiation, suggesting that thymic derived suppressor cells were 
also capable of moving into the periphery to maintain tolerance throughout an animal’s 
life, protecting them from autoimmunity. (Penhale, Farmer et al. 1973, Penhale, Stumbles 
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et al. 1990, Fowell and Mason 1993). These thymic derived suppressor T cells were 
eventually called nTregs because of their ability to confer natural tolerance. The 
development of these nTregs requires intermediate affinity interactions between their 
TCR and self-peptide/MHC complexes present on thymic stromal cells, allowing these 
cells to escape negative selection. The resultant Tregs have a TCR repertoire skewed 
towards the preferential recognition of self-peptides. Historically, Tregs have been 
characterized as the CD4+CD25
hi
 population in mice and humans (Sakaguchi, Sakaguchi 
et al. 1995, Itoh, Takahashi et al. 1999, Baecher-Allan, Brown et al. 2001, Dieckmann, 
Plottner et al. 2001), which also express forkhead box P3 (Foxp3), a transcription factor 
critical for the function and development of natural and inducible Tregs (Fontenot, Gavin 
et al. 2003, Hori, Nomura et al. 2003, Khattri, Cox et al. 2003, Fontenot, Rasmussen et 
al. 2005). Identification of these cells provided understanding of one of the immune 
mechanisms responsible for maintaining immune homeostasis. However attributing 
lifelong immune tolerance to these thymus derived subset of cells seemed unlikely as it is 
common knowledge that the thymus involutes with age, yet immune regulation remains 
intact throughout adulthood.  
 
In the early 2000s, the concept that antigen-specific inducible Tregs (iTregs) can also be 
generated in the periphery began to emerge. The Horwitz lab was the first to demonstrate 
that ability to generate CD4+CD25+ T cells from naive CD4 T cells cultured with TGFβ 
capable of suppressing normal T cell proliferation (Yamagiwa, Gray et al. 2001, Zheng, 
Gray et al. 2002). Differentiation of naïve CD4 T cells into fully functional and stable 
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iTregs requires IL-2, retinoic acid, and TGFβ  (Chen, Jin et al. 2003, Fantini, Becker et 
al. 2004, Zheng, Wang et al. 2004, Mucida, Park et al. 2007). TGFβ is a pleiotropic 
cytokine with broad implications in many cellular processes. TGFβ signaling is initiated 
by the binding of a TGFβ superfamily protein to (TGFβ1, TGFβ2, or TGFβ)  a TGFβR2 
homodimer on a cellular surface, resulting in signal transduction (Attisano and Wrana 
1996). When bound by its ligand, TGFβR2 acts as a serine/threonine kinase receptor and 
promotes the recruitment and phosphorylation of TGFβR1 (Wrana and Pawson 1997). 
Activated TGFβR1 phosphorylates the cytoplasmic proteins SMAD2/SMAD3, which 
form a complex with SMAD4 (Nakao, Imamura et al. 1997). This complex translocates 
to the nucleus where it can bind SMAD binding domains and promote the transcription of 
downstream genes such as FOXP3. In 2003, Chen et al. established that TGFβ promotes 
peripheral Treg induction and function through the transduction of Foxp3+ (Chen, Jin et 
al. 2003).  
 
Tregs act in several capacities to prevent immune reactions against self and regulate 
excessive immune responses to foreign antigens. Some main mechanisms include direct 
contact inhibition, secretion of anti-inflammatory cytokines, and competition for growth 
factors (Sojka, Huang et al. 2008). CTLA-4 is an inhibitory molecule that binds CD80 
and CD86 (B7 molecules) and is constitutively expressed on the surface of Tregs 
(Takahashi, Tagami et al. 2000). CTLA-4 competes with CD28, a co-stimulatory 
molecule on T cells, and preferentially binds B7 (Krummel and Allison 1995), thus 
blocking the activation of autoreactive T cells by antigen presenting cells (APCs). Tregs 
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also secrete the pro-inflammatory cytokines TGFβ and IL-10 (Dieckmann, Plottner et al. 
2001, Nakamura, Kitani et al. 2001, Jonuleit, Schmitt et al. 2002, Zheng, Wang et al. 
2004, Maynard, Harrington et al. 2007) both of which can dampen inflammatory 
processes (Asseman, Mauze et al. 1999). Additionally, Tregs can competitively bind IL-2 
through their high expression of CD25 leading to the cytokine deprivation of T effector 
(Teff) cells (Barthlott, Moncrieffe et al. 2005, Fontenot, Rasmussen et al. 2005). Through 
these mechanisms, Tregs can modulate the activation, differentiation, and proliferation of 
other Th cells (Annacker, Pimenta-Araujo et al. 2001, Oldenhove, de Heusch et al. 2003, 
Xu, Liu et al. 2003, Martin, Banz et al. 2004, Stassen, Jonuleit et al. 2004, Tadokoro, 
Shakhar et al. 2006, Pandiyan, Zheng et al. 2007). Therefore, under normal conditions 
Tregs have the tools needed to suppress T cell  immune responses. However, it is evident 
that in MS patients Th1 and Th17 responses are unable to be efficiently controlled, 
facilitating the need to analyze whether Tregs are capable of performing their normal 
suppressor functions in the context of CNS autoimmunity. Given the importance of TGFβ 
and Tregs in immunosuppression, research has been done investigating both in an attempt 
to understand their potential roles in the development of autoimmune diseases. 
 
Function of TGFβ in Immunosuppression 
The immunosuppressive effect of TGFβ on immune cells, particularly T lymphocytes, 
has been well documented. In 1986, Kehrl et al were the first to report the ability of 
TGFβ to inhibit IL-2 dependent proliferation of T cells (Kehrl, Wakefield et al. 1986). 
Additionally, mice with disruptions in the TGFβ1 gene developed multi-organ 
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autoimmunity (Shull, Ormsby et al. 1992, Kulkarni and Karlsson 1993), characterized by 
the infiltration of lymphocytes, including activated CD4 T cells (Letterio and Roberts 
1996).  Direct evidence that TGFβ signaling is necessary for the maintenance of T cell 
homeostasis came from observations of autoimmunity in mice with T cell specific 
disruptions in TGFβR2 (Gorelik and Flavell 2000). These findings set the stage for 
dissecting the role of TGFβ in specific T cell subsets. 
 
In adult mice with deficiencies in TGFβ signaling, the number of Tregs appears normal. 
However, the number of postnatal (3-5 days) Tregs is significantly reduced (Marie, 
Letterio et al. 2005, Marie, Liggitt et al. 2006, Liu, Zhang et al. 2008). This limited set of 
Tregs, which are CD25
+
, proliferate in response to increased levels of IL-2, resulting in 
normal numbers of Tregs (Liu, Zhang et al. 2008). However, these Tregs have a reduced 
capacity to suppress Teff cells as demonstrated by the uncontrolled autoimmunity 
observed in mice with TGFβ signaling deficiencies (Gorelik and Flavell 2000). The 
inability of Tregs from TGFβ signaling-impaired mice to suppress autoimmunity has 
been attributed to decreased Foxp3 expression and a decreased TCR repertoire, indicating 
that they may have insufficient diversity to respond to self-antigens and prevent 
autoimmunity. Interestingly, similar observations have been made in MS. 
 
Tregs in EAE and MS 
In 2002, the Miller group demonstrated for the first time that nTregs can prevent CNS-
specific autoimmunity by transferring purified heterogeneous Tregs from naïve wild-type 
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mice to mice with MOG-induced EAE (Kohm, Carpentier et al. 2002). In another model 
of EAE, MBP T cell receptor (TCR)  transgenic (Tg) mice deficient in recombination-
activating gene (rag) 1  spontaneously develop EAE, where as MBP TCR Tg rag
+/+
 mice 
are protected. This model was used to demonstrate that the passive transfer of antigen-
specific Tregs can prevent spontaneous autoimmunity (Hori, Nakano et al. 2002). Since 
2002, numerous studies have provided evidence that the transfer of antigen-specific or 
CNS-derived Tregs can allow for disease prevention and recovery in the context of EAE. 
While these studies demonstrate the ability of transferred Tregs to prevent autoimmunity, 
they do not address whether endogenous Tregs can be generated to suppress 
encephalitogenic Teff  cells during active disease.  
 
Korn, et al. utilized FOXP3/green fluorescent protein knock-in mice along with MOG 
tetramers to track MOG-specific Treg and Teff cells during active EAE (Korn, Anderson 
et al. 2007). They observed that MOG-specific Tregs were able to expand in the 
periphery and traffic to the site of damage in the CNS, but when challenged ex vivo, were 
unable to suppress activated CNS-derived Teff cells (Korn, Anderson et al. 2007). These 
findings indicate that there is an inherent defect in Treg function during CNS 
autoimmunity, but passive transfer of exogenous Tregs may provide therapeutic benefit.  
 
Similar studies comparing the frequency of Tregs in humans have shown that MS 
patients and healthy controls (HC) do not have significant differences in their Treg 
numbers (Putheti, Pettersson et al. 2004, Viglietta, Baecher-Allan et al. 2004, Haas, Hug 
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et al. 2005, Haas, Fritzsching et al. 2007). However, functional studies indicate that the 
Tregs of MS patients have diminished suppressive effect on the autoimmune response 
against myelin-specific T cells (Viglietta, Baecher-Allan et al. 2004, Haas, Hug et al. 
2005, Kumar, Putzki et al. 2006). Suppressive assays using the noted combinations of 
Treg and Teff cells (MS Treg with HC Teff cells and HC Treg with MS Teff cells) 
established that the lack of suppression observed in MS patients is not due to a resistance 
of Teff cells to suppression, but rather a defect in their Tregs (Baecher-Allan, Brown et 
al. 2001, Viglietta, Baecher-Allan et al. 2004, Haas, Hug et al. 2005). Further 
investigation showed that MS patients have reduced levels of FOXP3 compared to 
healthy donors (Huan, Culbertson et al. 2005, Venken, Hellings et al. 2008), which given 
the importance of FOXP3 in Treg function, could partially explain the lack of Treg 
function. Interestingly, patient-derived Tregs contained less TCR diversity compared to 
healthy Tregs, potentially explaining their inability to recognize and suppress myelin-
specific autoreactive Teff cells (Haas, Fritzsching et al. 2007). Given the inherent lack of 
Teff cell regulation, numerous therapies attempt to halt disease processes by directly 
targeting T cells.  
 
Therapies for MS 
Disease-modifying therapies (DMTs) are drugs that alter disease course with the potential 
for slowing down disease progression. Currently, there are 12 DMTs approved by the 
FDA for the treatment of MS [interferon beta-1a, interferon beta-1b, peginterferon beta-
1a, glatiramer acetate (GA), natalizumab, fingolimod, mitoxantrone, alemtuzumab, 
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dimethyl fumarate (DMF), and teriflunomide] (Wingerchuk and Carter 2014). MS DMTs 
can be divided into three main groups based on route of administration: self-injectables 
(IFNβ and GA), oral (DMF, fingolimod, and teriflunomide), and intraveneous 
(alemtuzumab, mitroxantrone, and natalizumab). Each of these drugs have mechanisms 
of action (MOA) implicated in the targeting or modulating components of the immune 
system, including T cells. The two most well characterized drugs are IFNβ derivatives 
and GA. Both of these drugs are thought to promote their effect by shifting Th cell 
differentiation from Th1 to Th2, enhancing Treg development, and driving deletion of 
myelin reactive T cells (Graber, McGraw et al. 2010). Similarly, Natalizumab and 
fingolimod both affect leukocytes, but rather than actively changing the phenotype of T 
cells, these drugs limit their mobility, preventing their migration into the CNS. For 
instance, natalizumab is a monoclonal antibody (mAb) that blocks very late antigen 4 
(VLA4) and consequently prevents T cells from binding to vascular cellular adhesion 
molecule 1 (VCAM1) and migrating into the CNS (Ransohoff 2007). Furthermore, 
fingolimod prevents T cell motility by acting as a sphingosine-1-phosphate (S1P) agonist 
to block S1P receptor signaling, essentially trapping T cells in the lymph nodes (Cohen 
and Chun 2011). Whereas alemtuzumab and teriflunomide act through more brute force 
immunomodulatory mechanisms by depleting circulating T cells and inhibiting T cell 
proliferation respectively (Claussen and Korn 2012). In addition to having 
immunosuppressive effects, some of the DMTs are thought to have neuroprotective 
effects as well.  Both DMF and laqunimod are thought to suppress microglia activation 
and alter their phenotype, limiting CNS inflammation (Wilms, Sievers et al. 2010, 
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Mishra, Wang et al. 2014, Peng, Matos et al. 2015).  Given that current DMTs all have 
unique immunologic targets and MOA, they are not all equally effective in MS patients 
and have different risk/benefit profiles. 
 
Currently, interferon beta (IFNβ) and glatiramer acetate (GA) are the most widely 
accepted first-line therapies for RRMS. While IFNβ and GA are considered only mildly 
effective compared to other DMTs, they are preferentially prescribed due to their long 
established use and safety profiles. On the other hand, some of the other drugs such as 
natalizumab, fingolimod, and alemtuzumab are more effective than traditional therapies, 
but at a price. These drugs have documented cases of serious and potentially fatal adverse 
events. For instance, patients on natalizumab who are infected with JC virus are at high 
risk for developing progressive multifocal leukoencephalopathy, an often fatal disease for 
which there is no cure. Additionally, patients on alemtuzumab and fingolimod are at risk 
for developing fatal autoimmune disorders and cardiac problems respectively. While 
these drugs may be justified due to their increased efficacy, other drugs such as 
teriflunomid should only be used in the event that a patient is not responding to first or 
second line therapies, as this treatment is a pregnancy category X drug and no more 
effective than other safer therapies. Therefore, it is necessary to weigh the potential 
outcomes and pre-screen patients accordingly when discussing treatment options. Aside 
from risk/benefit profiles, patient compliance and quality of life must also be considered 
when choosing a treatment. Therefore, route of administration must be also taken into 
account. Oral treatments are extremely attractive in that they are convenient and 
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comfortable to take, however they have not been shown to be superior to other DMTs. 
Therefore, DMF and fingolimod are really only good options when first line treatments 
are failing. While all of these drugs have been shown to reduce annual relapse rate and 
slow down time to progression of disease, it is obvious that current therapy options have 
many limitations. 
 
Notably, the available treatments are lacking, with only 1/12 DMTs indicated for SPMS 
and none indicated for PPMS, resulting in minimal chance of recovery especially in 
patients with progressive forms of the disease. Studies have demonstrated early use of 
DMTs in patients presenting with a CIS have a delayed conversion to CDMS (Jacobs, 
Beck et al. 2000, Comi, Filippi et al. 2001, Kappos, Polman et al. 2006, Comi, Martinelli 
et al. 2009, Miller, Wolinsky et al. 2014). Therefore, diagnosis of patients early during 
the disease process while treatments are available is essential for delaying progression of 
the disease. However, diagnosis is challenging, as there is no single test for MS. 
Additionally, despite the ability of existing drugs to slow down disease progression, the 
eventual worsening of symptoms is inevitable. Identification of individuals susceptible to 
developing MS may allow these patients to be proactive by submitting to routine 
screening and to prepare themselves for possible diagnosis. Therefore, research aimed at 
the identification of novel biomarkers and therapeutic targets is imperative for 
understanding disease activity, measuring treatment efficacy, and stopping disease 
progression. However, previous attempts at such studies have had limited success in 
identifying markers with high levels of sensitivity and specificity. This overall lack of 
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success potentiates the need for innovative strategies for elucidating factors of indicative 
of disease mechanisms promoting susceptibility and progression of MS. In recent years, 
miRNAs have emerged as important regulators that affect various biological processes. 
Even more recently, studies have begun to successfully show the clinical applications of 
miRNAs in various diseases such as cancer and rheumatoid arthritis (Lu, Getz et al. 
2005, Calin and Croce 2006, Pers and Jorgensen 2013, Redova, Sana et al. 2013). In 
addition, the accessibility and relatively low number of miRNAs make them ideal 
potential biomarker candidates. 
 
microRNAs (miRNAs) 
miRNA regulation is an active area of investigation for the regulation of cellular 
pathways and disease processes. The first miRNA was characterized in 1993 by the lab of 
Victor Ambros in C. elegans (Lee, Feinbaum et al. 1993), but it was not until the early 
2000s that miRNAs were acknowledged as distinct biological regulators (Lagos-
Quintana, Rauhut et al. 2001, Lau, Lim et al. 2001, Lee and Ambros 2001). In the past 22 
years, several studies have worked to characterize the properties and functions of 
miRNAs as epigenetic mediators. miRNAs are small non-coding RNAs approximately 
19-24 nucleotides in length. They are transcribed in the nucleus as primary miRNA, 
which are further processed by the Drosha/Pasha complex, resulting in precursor miRNA 
(pre-miRNA). Pre-miRNA is subsequently transported from the nucleus to the cytoplasm 
by the protein Exportin-5. Once in the cytoplasm, pre-miRNA is cleaved by the enzyme 
Dicer, resulting in the generation of an RNA duplex from which one strand of RNA is 
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degraded. The remaining single stranded RNA, now called a miRNA, is loaded into the 
RNA induced silencing complex (RISC) where it promotes its function as a negative 
regulator of gene expression. miRNAs function at the post-transcriptional level through 
base-pair binding to complementary sequences of mRNA in the 3’ untranslated regions 
(3’ UTRs) of genes (Ambros 2004, Bartel 2004, Bartel 2009).  
 
There are three main mechanisms of miRNA function: 1) the binding and cleaving of 
mRNA, 2) blocking of machinery crucial for translation, and 3) destabilization of mRNA, 
resulting in mRNA degradation (Filipowicz, Bhattacharyya et al. 2008, Bartel 2009, 
Chekulaeva and Filipowicz 2009, Fabian, Sonenberg et al. 2010). In general terms, 
miRNAs reduce the expression of specific proteins. Importantly, miRNAs do not bind 
exclusively to one mRNA target nor are mRNAs only regulated by one miRNA. Rather, 
miRNAs have the ability to bind to and regulate many different genes, potentially in the 
same biological pathway. miRNAs are highly conserved among mammals (Lim, Glasner 
et al. 2003) and have conserved binding sequences in approximately 60% of human 
protein-coding genes (Friedman, Farh et al. 2009).  
 
As suggested by their evolutionary conservation, miRNAs are crucial to the maintenance 
of normal cellular development and function (Ambros 2004, Bartel 2004, Chen, Li et al. 
2004). Loss of the miRNA processing enzyme dicer in T cells leads to a lack of T cell 
maturation and differentiation (Cobb, Hertweck et al. 2006, Muljo, Kanellopoulou et al. 
2010). Since these seminal observations, miR-181a (Li,2007), miR-155 (Rodriguez, 
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Vigorito et al. 2007, Thai, Calado et al. 2007), and miR-142-3p (Huang, Zhao et al. 
2009) have been found to influence early T cell development, Th differentiation, and 
Treg suppressive function, respectively. Interestingly, miRNA levels vary based on cell 
type and stage of differentiation (Monticelli, Ansel et al. 2005, Wu, Neilson et al. 2007, 
Merkerova, Belickova et al. 2008). Therefore, comparing miRNA profiles of specific cell 
types in disease versus healthy state may provide insight into the cellular processes 
contributing to disease pathogenesis. 
 
As indicated, miRNAs regulate immunoregulatory pathways important for immune 
development and function. In addition to being biological regulators, miRNAs are easily 
quantified from cells, tissue, and blood, making them attractive candidates for potential 
markers for disease. Initial evidence linking human disease to changes in miRNA levels 
was provided by the Croce lab who demonstrated that the loss of specific miRNAs (mir-
15 and miR-16) is associated chronic lymphocytic leukemia (Calin, Dumitru et al. 2002) 
and correlates with increased levels of the antiapoptotic B cell lymphoma 2 (Bcl2) 
protein (Cimmino, Calin et al. 2005).  Additionally, the use of miRNA signatures in 
cancer patients has proven to be effective for identifying tumor origin and predicting 
outcome and treatment response (Lu, Getz et al. 2005, Calin and Croce 2006). Loss of 
miRNA regulation has also been implicated in autoimmune disease, as shown by casual 
studies demonstrating that deletion of miRNA processing elements specifically in Tregs 
leads to uncontrolled autoimmunity in mice (Chong, Rasmussen et al. 2008, Liston, Lu et 
al. 2008, Zhou, Jeker et al. 2008). In the context of human autoimmune disease, the 
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deregulation of miRNAs has been correlated with biological process critical for the 
promotion and progression of several autoimmune diseases. For example, both miR-155 
and miR-146a has been found to be differentially expressed in patients with systemic 
lupus erythematosus and rheumatoid arthritis (Qu, Li et al. 2014). These observations 
promoted further investigation of miRNAs involvement in other human autoimmune 
diseases. 
 
miRNAs in MS 
In recent years, there has been an emerging interest to use miRNA profiling to identify 
differences between healthy individuals and MS patients. Several studies have evaluated 
miRNAs levels in cells from the peripheral blood of MS patients (Du, Liu et al. 2009, 
Keller, Leidinger et al. 2009, Otaegui, Baranzini et al. 2009). In 2009, Otaegui, et al. 
demonstrated for the first time that miRNAs are differentially expressed in the peripheral 
blood mononuclear cells (PBMCs) of RRMS patients compared to healthy donors. The 
miRNAs that were significantly altered in relapsing patients (miR-18b and miR-599) 
were different than those identified in remitting individuals (miR-96), indicating that 
therapeutically targeting pathways regulated by miR-96 could promote recovery 
(Otaegui, Baranzini et al. 2009).  Also in 2009, Keller, et al. showed that 165 miRNAs 
were differentially expressed in the peripheral blood leukocytes of MS patients, 43 of 
which could be used to detect RRMS patients with an approximately 90% sensitivity, 
specificity, and accuracy, identifying a novel role for miRNAs in MS as potential 
biomarkers (Keller, Leidinger et al. 2009). Since these initial findings, several miRNAs 
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have been implicated in specific stages of MS pathogenesis. For example, miR-326, a 
miRNA that promotes Th17 differentiation, was found to be significantly upregulated in 
both PBMCs and active lesions of MS patients compared to healthy individuals (Du, Liu 
et al. 2009, Junker, Krumbholz et al. 2009). Bitranslational studies showed that silencing 
of miR-326 results in mice with fewer Th17 cells and less severe EAE (Du, Liu et al. 
2009). To date, the largest miRNA profiling studying of MS patient PBMCs assessed the 
levels of 733 miRNAs in 59 treatment naïve patients and 37 healthy controls. Two of the 
miRNAs (miR-17 and miR-20) that were downregulated in MS patients were found to be 
important regulators of T cell activation (Cox, Cairns et al. 2010). 
 
In addition to miRNA studies on mixed cellular populations, others have been done on 
defined subsets of cells from the peripheral blood (De Santis, Ferracin et al. 2010, 
Lindberg, Hoffmann et al. 2010, Guerau-de-Arellano, Smith et al. 2011, Smith, Guerau-
de-Arellano et al. 2012) and lesions (Junker, Krumbholz et al. 2009) of MS patients. In 
2010, Lindberg et al. and De Santis, et al. assessed miRNA levels in CD4+CD25hi 
Tregs, identifying 23 differentially expressed miRNAs in RRMS patients. Two of the 
described miRNAs (miR-106b and miR-25) were previously shown to regulate the 
transforming growth factor beta (TGFβ) pathway, a pathway critical for the development 
and function of Tregs, indicating a potential defect of TGFβ signaling in these cells (De 
Santis, Ferracin et al. 2010). While the peripheral blood studies can compare miRNA 
profiles of patients in different disease states, they do not necessarily identify which 
miRNA are playing a role in active CNS disease. In order to identify miRNA specifically 
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altered during active CNS damage, Junker et al compared the miRNA profiles of active 
and inactive lesions of MS patients to each other and to normal appearing white matter 
from healthy subjects and showed a correlation between increased levels of miR-326, 
miR-155, and miR-34a with decreased levels of CD47 in resident brain cells, a protein 
that provides inhibitory signals to macrophages (Junker, Krumbholz et al. 2009). These 
studies provide evidence that miRNAs may participate in the many different aspects of 
MS pathology. 
 
In 2010, Weber et al reported the presence of miRNAs in 12 bodily fluids including 
plasma and CSF, supporting the potential use of miRNAs as easily detectable biomarkers 
(Weber, Baxter et al. 2010). In 2012, Siegel et al were the first to demonstrate the 
differential expression of miRNAs in the plasma of MS patients compared to healthy 
controls, identifying 7 miRNAs (miR-614, miR-572, miR-648, miR-1826, miR-422a, 
miR-22, and miR-1979) that could potentially be used as biomarkers for MS (Weber, 
Baxter et al. 2010). A similar study of select miRNAs identified miR-145 as being 3-fold 
higher in the plasma, PBMCs, and serum of treatment naïve RRMS patients in remission 
(Søndergaard, Hesse et al. 2013). Recently, Gandhi et al performed an extensive profiling 
study of plasmic miRNAs in RRMS and SPMS patients that were treatment naïve, and 
identified two miRNAs (miR-92 and let-7) that could be used to distinguish RRMS from 
SPMS (Gandhi, Healy et al. 2013). Interestingly, these same miRNAs could be used to 
differentiate RRMS from amyotrophic lateral sclerosis (ALS), a neurodegenerative 
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disease, but not SPMS and ALS, suggesting potential overlap in disease processes for 
SPMS and ALS (Gandhi, Healy et al. 2013). 
 
While providing insight into disease mechanisms, the previously mentioned studies do 
not address whether the observed differences are inherent in the patients or a 
consequence of disease, which is crucial for identifying specific miRNAs as potential MS 
susceptibility factors. To this end, our group previously performed a miRNA profiling 
study on naïve and memory CD4 T cells isolated from the PBMCs of healthy donors and 
treatment naïve MS patients (Guerau-de-Arellano, Smith et al. 2011). This study 
identified 85 differentially expressed miRNAs in the naïve CD4 T cells of MS patients. 
In 2011, our group published evidence that two miRNAs (miR-128 and miR-27b) which 
are significantly upregulated in the naïve CD4 T cells of MS patients influence the 
development of MS through the inhibition of Th2 differentiation and promotion of Th1 
responses (Guerau-de-Arellano, Smith et al. 2011).  Evidence from Smith et al 
demonstrating a decrease in miR-29b levels also supports that the naïve CD4 T cell 
miRNA profile of MS patients is preferential to Th1 polarization (Smith, Guerau-de-
Arellano et al. 2012). Additional bioinformatics analyses of data from our group 
predicted that 25 of the 85 differential expressed miRNAs target four genes of the TGFβ 
signaling pathway, TGFβ receptor 1 (TGFβR1), TGFβ receptor 2 (TGFβR2), SMAD2, 
and SMAD4.  
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Rationale 
MS is an inflammatory demyelinating disease of the CNS, which devastatingly affects 
450,000 people in the United States alone (Hersh and Fox 2010). The cause of MS 
remains unknown, and the mechanisms that propagate the pathology of the disease are 
poorly understood. This lack of knowledge has made preventing MS impossible and 
effectively halting disease progression challenging. The long-term goals of the Lovett-
Racke lab are to determine mechanisms that underlie the pathophysiology of MS and 
identify candidate regulators of disease susceptibility and novel therapeutic targets. The 
CNS damage observed in MS patients is thought to be immune-mediated and promoted 
by myelin-specific pro-inflammatory T cells. The lack of immune regulation in MS 
patients has clearly been established and partially attributed to an inherent defect in 
Tregs. While being normal in number, Tregs of MS patients demonstrate diminished 
suppressive effect, reduced Foxp3 expression, and a less diverse TCR repertoire (Putheti, 
Pettersson et al. 2004, Viglietta, Baecher-Allan et al. 2004, Haas, Hug et al. 2005, Haas, 
Fritzsching et al. 2007, Venken, Hellings et al. 2008). However, the mechanisms for the 
Treg defects in MS patients are unknown. Understanding what causes this pro-
inflammatory shift in T cell differentiation and lack of regulation in MS patients is 
critical for identifying potential MS susceptibility factors and therapeutic targets.  
 
The main objective of my graduate work was to determine the extent to which miRNAs 
identified as being differentially expressed in MS patients regulate genes critical for the 
development of functional Tregs. To this end, our lab previously performed miRNA 
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profiling studies on the naïve CD4+ T cells of MS patients and healthy donors and 
identified 85 miRNAs to be differentially expressed in MS patients. In a published report, 
the lab demonstrated that dysregulation of a select group of these miRNA in the naïve 
CD4 T cells of MS patients promotes Th1 polarization. Further pathway analysis of the 
miRNA data, led to the discovery of 19 differentially expressed miRNAs in the naïve 
CD4 T cells of MS patients that are predicted to target and inhibit genes of the TGFβ 
signaling pathway. TGFβ is a pleiotropic cytokine that is critical for the development and 
suppressor function of Tregs (Yamagiwa, Gray et al. 2001, Zheng, Gray et al. 2002, 
Chen, Jin et al. 2003). Interestingly, it has been observed that adult mice deficient in 
TGFβ signaling develop multi-organ autoimmunity (Shull, Ormsby et al. 1992, Kulkarni 
and Karlsson 1993, Gorelik and Flavell 2000). This has been attributed to a defect in 
Tregs. These mice exhibit a Treg phenotype that mirrors observations made in MS. 
Taken together, these findings suggested a potential link between the Treg defect 
observed in MS patients and TGFB signaling deficiencies. Therefore, we hypothesized 
that dysregulated miRNAs in the naïve CD4+ T cells of MS patients target the TGFβ-
signaling pathway, resulting in defective Tregs and enhanced susceptibility to developing 
MS. The rationale for the proposed project is that investigating the role of miRNAs in the 
development of Tregs, will enable the: (1) identification of miRNAs responsible for the 
regulation of the TGFβ signaling pathway, (2) correlation of miRNA expression levels 
with Tregs deficits and (3) identification of miRNAs that potentially regulate MS 
pathogenesis through their binding of TGFβ-associated genes. 
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Specific Aims 
To accomplish my overall objective, the following aims were proposed:  
Aim 1: Determine the extent to which the TGFβ signaling pathway is inhibited by the 
miRNAs identified as dysregulated in the naïve CD4+ T cells of MS patients. The 
working hypothesis was that differentially expressed miRNAs bind to specific genes of 
the TGFβ-signaling pathway in naive CD4 T cells  and inhibit the translation of their 
protein products.  
 
Aim 2: Identify which TGFβ-targeting miRNAs alter the development of inducible Tregs 
(iTregs) in vitro. The working hypothesis was that over expression of miRNAs that target 
specific genes known to promote TGFβ-pathway signaling would cause a decrease in 
signaling and attenuates the development of iTregs.  
 
Aim 3: Elucidate the effect of miRNA dysregulation on disease susceptability in vivo and 
iTreg generation directly ex vivo.  The working hypothesis was that the overexpression of 
TGFβ-targeting miRNAs in vivo would increase disease severity and reduce capacity to 
generate iTregs ex vivo. 
 
The work proposed in aim 1 was expected to yield the following outcome: specific 
miRNAs would be identified as key negative regulators of the TGFβ-signaling pathway. 
Importantly, aim 2 would allow the identification of specific TGFβ-targeting miRNAs 
that have a diminishing effect on Treg development. The work proposed in aim 3 was 
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predicted to identify specific combinations of miRNAs that enhance onset and severity of 
CNS autoimmunity. The overall expected outcomes of this project proposed to positively 
impact the field by contributing to the understanding of the underlying pathophysiology 
of Treg dysfunction in MS patients and by identifying candidate regulators of disease 
susceptibility, as well as, potential therapeutic targets.  
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Chapter 2: General Methods 
 
Human Subjects (Chapters 3-5) 
The PBMCs used in Chapter 3 were obtained by leukopharesis at the University of Texas 
Southwestern Medical Center and the Washington University in Saint Louis. All PBMCs 
used in Chapter 3 were frozen and stored in liquid nitrogen. The MS PBMCs used in 
Chapters 4 and 5 were obtained by blood draw at The Ohio State University (OSU) MS 
Clinic. The healthy control PBMCs used in Chapters 4 and 5  were obtained via blood 
draw from donors at the American Red Cross. The donor blood was screened by Red 
Cross and found negative for specific pathogens. Both OSU MS Clinic and Red Cross 
samples were used directly ex vivo within 24 hr of being obtained.   
 
PBMC Isolation (Chapters 3-5) 
PBMCs were isolated from peripheral blood with Ficoll-Paque Plus (GE Healthcare). The 
blood was layered over Ficoll and lymphocytes were isolated via density centrifugation 
according to the manufacturer’s protocol. Cells were immediately used and not frozen.  
 
PBMC Transfection (Chapters 3-5) 
PBMCs were plated on a 6-well plate in 2.5 ml of complete growth medium at a density 
of 8 x 10
6
 cells per well. Transfection complexes were made by mixing 8 µl of TransIT-
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TKO Transfection Reagent (Mirus) with 0.05 µM of single miRNA mimics (Dharmacon; 
miR-NS, miR-27b, miR-103a, miR-128, miR-141, miR-212, miR-500a, miR-628-3p, 
miR-708, let-7a, and let-7b) or 0.05 µM of miRNAs mimics in combination (miR-
103/212/708; miR-141/500a/let-7b; miR-128/628-3p/let-7ab) in 250 µl of serum free 
medium and incubated for 30 min at room temperature. A nonsense miRNA (miR-NS) 
was used as a negative control for miRNA transfection. Transit TKO:miRNA complexes 
(250 µl) were added in a drop-wise fashion to the cells. Cells were incubated for 48 hr at 
37 °C.  
 
In Vitro Human Treg Induction (Chapters 4 and 5) 
In general, PBMCs were rested for 2 hr, in order to get rid of adherent cells. The cells 
remaining in suspension were counted and plated at concentration of 1.5 x 10
6
 cells/ml on 
a 48-well antibody-coated plate. Plates were coated with 500 µl of anti-human CD3 (1 
µg/ml) and anti-human CD28 (1 µg/ml) diluted in PBS and incubated overnight at 4 °C 
or 2 hr at 37 °C. In order to generate iTregs, cells were centrifuged and resuspended in 
complete human growth media [1650 RPMI, 1% L-glutamine, 1% HEPES Buffer, 1% 
penicillin/streptomycin, and 5% human serum (AB)] supplemented with of 1 U/ml IL-2, 
0.5 ng/ml TGFβ1, and 2.5 nM all-trans retinoic acid. Cells were subsequently incubated 
for 72 hr at 37 °C.  
 
 
 
35 
 
Flow Cytometry (Chapters 3-5) 
Flow cytometry was used to look at cell surface markers CD4 (BD Biosciences), 
CD45RA (BioLegend), and CD25 (BD Biosciences) and intracellular components of 
FOXP3 (eBioscience), SMAD4 (R&D Systems), and TGFBR1 V 1-22 (Santa Cruz). 
Cells were collected, centrifuged, and resuspended in Fc Block (Miltenyi Biotec) diluted 
with staining buffer (PBS with 1% bovine serum albumin). Cells were incubated in 
diluted Fc Block for 10 min at room temperature. After blocking, the anti-human surface 
antibodies were diluted with staining buffer, added to cells, and incubated for 30 min at 4 
°C. The cells were subsequently washed in staining buffer, resuspended in 1X 
fixation/permeabilization concentrate (eBioscience), and incubated for 30 min at 4 °C. 
After washing with 1X permeabilization buffer, cells were resuspended in Fc Block 
diluted in permeabilization buffer and incubated for 10 min at room temperature. After 
blocking, anti-human intracellular antibodies were diluted with 1X permeabilization 
buffer, added to cells, and incubated for 30 min at 4 °C (SMAD4 and TGFBR1) or 45 
min at room temperature (FOXP3). The TGFβR1 detection required an additional 
staining with FITC conjugated goat anti-rabbit secondary antibody (Abcam) for 30 min at 
4 °C. Cellular markers were measured with a FACSCanto II (BD Biosciences), and all 
data was analyzed using FlowJo software (Tree Star). 
 
Mice (Chapter 5) 
All mice used were B10.Pl wild-type mice. Breeder mice were initially purchased 
through Jackson Laboratory. All mice were bred, housed, and maintained in a specific-
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pathogen free facility at OSU. All animal procedures performed were outlined in 
protocols approved by the OSU Institutional Animal Care and Use Committee (IACUC). 
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Chapter 3: Differentially Expressed miRNAs in the Naïve CD4 T cells of MS Patients 
Target the TGFß Signaling Pathway 
 
Introduction 
While epidemiological studies have identified both environmental and genetic 
components as potential risk factors for MS, the true cause of the disease is unknown. 
The CNS demyelination observed in MS patients is hypothesized to be an immune-
mediated response driven in part by pro-inflammatory T cells activated against myelin 
antigens. Genetics studies have identified variants of immune-related genes as potential 
contributors to disease susceptibility (Mackay and Myrianthopoulos 1966, Ebers, Bulman 
et al. 1986, Willer, Dyment et al. 2003), indicating the importance of investigating 
differences in immune components between MS patients and healthy individuals. 
However, these studies have had limited success, necessitating the need to uncover 
additional genetic contributors. 
 
The recent discovery of miRNAs as novel biological regulators, and the evidence 
supporting the role of miRNA dysregulation in mediating immune-related disease 
processes drove researchers to investigate miRNAs in the context of MS. Several studies 
have identified dysregulated miRNAs in both bodily fluids and isolated cellular subsets 
from the lesions and peripheral blood of MS patients (Junker, Krumbholz et al. 2009, De 
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Santis, Ferracin et al. 2010, Lindberg, Hoffmann et al. 2010, Guerau-de-Arellano, Smith 
et al. 2011, Smith, Guerau-de-Arellano et al. 2012). However, these studies do not 
address whether the observed miRNA dysregulation is an inherent defect in MS patients 
that increases their disease susceptibility or a mere consequence of disease.  
 
To this end, our lab performed a miRNA profiling study of the naïve and memory CD4 T 
cells of MS patients and healthy individuals. Naïve CD4 T cells have not encountered 
antigen or undergone activation, suggesting that any observed differences in MS patients 
are indicative of inherent defects and not a repercussion of MS. In the naïve CD4 T cells, 
85 miRNAs were found to be significantly up or down regulated in MS patients 
compared to healthy controls.  In a published report, our lab demonstrated that 
dysregulation of two of the 85 identified miRNAs (miR-27b and miR-128) promotes 
decreased Th2 differentiation and enhances Th1 polarization (Guerau-de-Arellano, Smith 
et al. 2011). These findings suggested that miRNAs have biological significance and 
therapeutic potential through their regulation of T cell phenotypes in MS. 
 
Further pathway analysis of the miRNA profiling data identified 19 differentially 
expressed miRNAs predicted to target and inhibit the TGFß-signaling pathway. TGFβ is 
a cytokine critical for immune suppression, as made evident by the uncontrolled multi-
organ autoimmunity observed in mice with deficiencies in TGFß signaling (Shull, 
Ormsby et al. 1992, Kulkarni and Karlsson 1993, Gorelik and Flavell 2000). 
Interestingly, these mice have similar immune characteristics as MS patients. The initial 
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aim of my dissertation was to determine the extent to which the TGFß signaling pathway 
is inhibited by the dysregulated miRNAs in the naïve CD4+ T cells of MS patients. The 
working hypothesis is that a portion of the 19 differentially expressed miRNAs directly 
bind to genes of the TGFß-signaling pathway and disrupt the translation of their protein 
products, thereby diminishing signaling of the TGFß-pathway in the naïve CD4 T cells of 
MS patients. The rationale for the work described in Chapter 3 is that identifying specific 
TGFß-associated genes that are decreased in MS patients would allow us to validate that 
the TGFß pathway is suppressed in MS patients and assist us in narrowing down the 
scopes of our study.  
 
Materials and Methods 
Human Naïve CD4 T Cell Isolation 
Naïve CD4+CD45RA+ T cells were isolated from the frozen MS patient and healthy 
control PBMCs that were obtained as described in Chapter 2. First, frozen cells were 
thawed, washed with complete human medium, and centrifuged. Dead cells were 
eliminated with the Dead Cell Removal Kit (Miltenyi Biotec). The naïve CD4 T cells 
were subsequently isolated with the Human Naïve CD4+ T Cell Isolation Kit II (Miltenyi 
Biotec). The remaining live cells were incubated with the a cocktail of biotinylated anti-
human CD45RO, CD8, CD14, CD15, CD16, CD19, CD25, CD34, CD36, CD56, CD123, 
anti-TCR/, anti-HLA-DR, and CD235a antibodies, magnetically labeling Memory 
CD4 T cells and non-CD4 T cells. The labeled cells were subsequently magnetically 
depleted with the autoMACS
®
 Pro Separator. The “depletes” program automatically 
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retains the labeled cells on the column as the positive fraction and dispels the untouched 
naïve CD4 T cells in the negative fraction. The Dead Cell Removal Kit and the Human 
Naïve CD4+ T Cell Isolation Kit II were used according to the manufacturer’s manual 
magnetic labeling and autoMACS
®
 Pro Separator protocols. 
 
Flow Cytometry: Naïve CD4 T Cell Purity Check 
A small sample of the negative fraction was saved to determine the purity of the naïve 
CD4 T cells recovered. The positive fraction was used for compensation set up. Flow 
cytometry was performed as described in Chapter 2. Cells were labeled with the surface 
antibodies anti-human CD4-Pacific Blue™ (PB; BD Biosciences), anti-human CD45RA-
allophycocyanin (APC; BioLegend), and anti-human CD45RO-phycoerythrin (PE; 
BioLegend). Naïve cells were defined as cells that were CD4+CD45RA+CD45RO-. 
 
RNA Isolation 
RNA was only extracted from MS patient and healthy donor sample Naïve CD4 T cell 
isolates with CD4+CD45RA+ purity of 95% or higher. RNA was isolated from the naïve 
CD4 T cells with the mirVana™ miRNA Isolation Kit (Ambion™).  Total RNA 
including miRNAs was isolated according to the manufacturer’s protocol and stored at    
-80 °C. 
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Real-Time Polymerase Chain Reaction (PCR): TGFβ Signaling Genes 
The expression levels of TGFR1, TGFR2, SMAD2, and SMAD4 were measured with 
quantitative real-time PCR. The RNA samples used were the same samples from the 
miRNA profiling array. cDNA was reverse transcribed from the RNA of these samples 
using random primers. TaqMan
®
 real-time polymerase chain reactions were performed 
using human TGFR1, TGFR2, SMAD2, SMAD4, and HPRT Applied Biosystems® 
(ABI) primer/probe sets. TaqMan
®
 real-time PCR was performed with a 20 l reaction 
volume containing 10 l TaqMan® Universal PCR Master Mix (2X; ABI), 1 l 
primer/probe assay mix (20X; ABI), 1 l cDNA, and 8 l RNAse free water. Human 
HPRT was measured and used as the endogenous control. Results were analyzed using 
the comparative Ct method. Relative fold change expression was calculated relative to 
the median Ct of the healthy controls group. 
 
Pathway Analysis 
The online software TargetScanHuman (Whitehead Institute for Biomedical Research) 
was used to identify predicted target genes of the miRNAs that were significantly 
different between the MS patients and healthy controls groups. The software determined 
target genes based on 3’UTR base-pairing. The resulting list of predicted target genes 
was loaded into Ingenuity
®
 Pathway Analysis (QIAGEN) to identify if any of the target 
genes belonged to the same signaling pathway.  
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Flow Cytometry: SMAD4 and TGFβR1 
The naïve CD4 T cells of MS patients and healthy individuals in Figure 3.3 were 
analyzed for protein levels of SMAD4 and TGFR1 via flow cytometry as described in 
Chapter 2. Vials of frozen PBMCs from the samples used in the miRNA profiling and 
real-time PCR assays described above were thawed and used for flow cytometric 
analysis. The cells were stained with the surface antibodies anti-human CD4-PB (BD 
Biosciences) and human anti-CD45RA-APC (BioLegend). The cells were also stained 
with the intracellular antibody anti-human SMAD4-PE (R&D systems) and the primary 
antibody anti-human TGFR1 V 1-22 (Santa Cruz). A second intracellular staining step 
was performed with the secondary antibody goat anti-rabbit IgG-fluorescein 
isothiocyanate (FITC; abcam
®
). The cells were first sub-gated on naïve CD4 T cells 
(CD4+CD45RA+). The geometric mean fluorescence intensity (MFI) of SMAD4 and 
TGFβR1 was determined for the CD4+CD45RA+ cells. The levels of SMAD4 and 
TGFβR1in the naïve CD4 T cells of the miRNA transfected healthy PBMCs shown in 
Figure 3.7 and Figure 3.8 were analyzed via flow cytometry as described above. 
 
Vector Preparation 
In order to prepare the vector for the luciferase assays, plasmids were replicated and 
digested with restriction enzymes. One Shot
®
 TOP10 chemically competent E.coli cells 
(Invitrogen™) were transformed with the pGL3 Luciferase Reporter Vector (Promega). 
The resulting transformants were grown on liquid broth (LB) agar plates containing 
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ampicillin. Ampicillin was chosen since pGL3 plasmids are resistant to that specific 
antibiotic. Single bacteria colonies were picked and grown in small volume cultures (2 ml 
LB and 2 l ampicillin (100 mg/ml)) at 37 °C overnight. The small volume cultures were 
expanded to large volume cultures (2 ml small volume culture and 48 ml LB) at 37 °C for 
12 hr. Resultant bacteria were pelleted and stored at -20 °C until further use. Bacterial 
pellets were thawed, and pGL3 plasmids were isolated with the Plasmid Midi Kit 
(QIAGEN) according to the manufacturer’s protocol. The purified plasmids were 
subsequently digested with the restriction enzyme XbaI in order to prep the plasmid for 
ligation of a 3'UTR insert.  
 
3'UTR Insert Preparation  
Segments of the 3'UTRs for TGFR1 and SMAD4 were PCR-amplified and prepared for 
insertion into the pGL3 luciferase vector. The binding sites for the miRNAs predicted to 
target the TGF signaling pathway were mapped throughout the 3'UTR of TGFβR1 
(NM_004612) and SMAD4 (NM_00539) using TargetScan Human 6.2 (Whitehead 
Institute for Biomedical Research). RNA was extracted from the PBMCs of healthy 
donors according to the manufacturer’s protocol for TRIzol® RNA isolation (Life 
Technologies). Resulting RNA was checked for RNA degradation using gel 
electrophoresis. cDNA was obtained by reverse transcribing 2 µg of the  isolated RNA 
with random primers (Applied Biosystems, ABI) using the High Capacity cDNA Reverse 
Transcription (RT) Kit Protocol (ABI). Custom primers (Invitrogen™) were designed 
against segments of the TGFR1 and SMAD4 3'UTRs that contain multiple miRNA 
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binding sites and that were approximately ≤ 1 kilo base pairs (bp) long. It is important to 
note that these primers added XbaI sites onto the ends of each PCR product. 
 
Subsequently, a standard polymerase chain reaction (PCR) was performed for each 
primer set in order to amplify the desired 3'UTR segments. The Finnzyme Fusion 
Protocol was performed according to manufacturer specifications.  The final reaction 
volume was 50 µl consisting of 10 µl Phusion Buffer (5X), 1 µl dNTPs (10 mM), 2 µl 
forward primer, 2 µl reverse primer, 1 µl cDNA (RT reaction product), 0.5 µl DNA 
polymerase, and DNAse free water. The PCR program was as follows: 94 °C for 30 sec, 
35 amplification cycles (94 °C for 30 sec, 60 °C for 30 sec and 72 °C for 1 min), and 72 
°C for 10 min.  To verify that the PCR products were the correct size they were analyzed 
using gel electrophoresis. To prepare the PCR product for insert into the PGL3 vector, the 
PCR products were purified using the PCR Purification Kit (QIAGEN) and digested with 
Xbal.  
 
Ligation and Transformation of Digested Plasmids and 3'UTR Segments 
In order to make complete constructs for the luciferase assays, individual digested 3'UTR 
inserts were ligated into digested pGL3 vectors. Ligation reactions consisting of 1 µl 
buffer, 0.5 µl vector (XbaI-digested), 1 µl insert (XbaI-digested), and 0.5 µl ligase 
enzyme were incubated at room temperature for 2 hr. Subsequently, One Shot
®
 TOP10 
chemically competent E. coli cells were transformed with 4 µl of the ligation reaction. 
The resulting transformants were grown on LB agar plates, selected, and grown in LB 
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cultures as described above. From the resultant bacteria, plasmids were isolated and 
purified also as previously described.  To verify that the plasmids contained the correct 
insert, enzyme digestion of the constructs was performed and the resulting fragment sizes 
were determined via gel electrophoresis. Additionally, the plasmid sequences were 
verified through DNA sequencing at the OSU Nucleic Acid Shared Resource facility. 
 
Luciferase Assay 
The ability of miRNAs to bind and inhibit their predicted target genes was analyzed via 
luciferase assays.  For human TGFR1 (NM_004612), two segments of the 3'UTR were 
individually cloned into pGL3 vectors (Promega). TGFR1 3’UTR base pairs 1563-2752 
contain binding sites for miR-27b and miR-128. TGFβR1 3’UTR base pairs 3275-4038 
contain binding sites for miR-141, miR-500a, and let-7. For human SMAD4 
(NM_00539), four segments of the 3’UTR were made and cloned into pGL3 vectors. 
SMAD4 3’UTR base pairs 1-787 contain binding sites for miR-708 and miR-212. 
SMAD4 3’UTR base pairs 1525-2275 contain binding sites for miR-500a, miR-27b, and 
miR-128. SMAD4 3’UTR base pairs 3927-4582 contain binding sites for miR-128, miR-
628-3p, miR-141, and miR-27b. SMAD4 3’UTR base pairs 4570-5563 contain binding 
sites for miR-103a, miR-141, and miR-18a.  
 
Cos-7 cells were grown in complete growth medium (Dulbecco's Modified Eagle's 
Medium (DMEM), 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin) at 37 °C 
until cells were 60-80% confluent. Cells were subsequently transfected with a complete 
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construct (pGL3 with 3’UTR segment) and a single miRNA. Transfection complexes 
were generated by incubating plasmid DNA (150 ng), miRNA mimic (50 pmol), and 250 
µl transfection media [6 µl Lipofectamine 2000 (Life Technologies) and 250 µl DMEM] 
together for 20 min at room temperature. Nonsense scrambled miRNA (miR-NS) was 
used as the negative control. miRNA:plasmid complexes (250 µl) were added in a drop-
wise fashion to the cells. Cells were incubated at 37 °C overnight. After incubation, 
media was removed, and the transfected cells were lysed in 250 µl Luciferase Lysis 
Buffer (1X; Promega). Lysates were stored at -80 °C until further use.  The cell lysates 
were analyzed with the Luciferase Assay System (Promega). 100 µl of Luciferase Assay 
Reagent (Promega) was added to 20 µl of lysate in opaque 96-well microplates (BD 
Falcon).  A luminometer measured the light produced in relative light units (RLU). It is 
important to note that luciferase assays were performed in biological triplicates for  all 
the miRNA and construct combinations. For the RLU readings, experimental triplicates 
were used.  
 
miRNA Transfection 
PBMCs from healthy individuals were transfected with individual miRNA mimics (miR-
NS, miR-27b, miR-103a, miR-128, miR-141, miR-212, miR-500a, miR-628-3p, miR-
708, let-7a, and let-7b; GE Healthcare Dharmacon) or combinations of miRNA mimics 
(miR-103/212/708; miR-141/500a/let-7b; miR-128/628-3p/let-7ab). Source leukocytes 
were obtained and kept at room temperature. PBMCs were isolated from the source 
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leukocytes within 24 hr of donation. Cells were plated, transfected, and cultured as 
described in Chapter 2.  
 
Statistical Analysis 
Statistical analysis for the miRNA profiling array data shown in Figure 3.4 and Table 1 
was performed using parametric Limma test as previously described by our lab (Guerau-
de-Arellano, Smith et al. 2011). The fold changes for Figure 3.2 were calculated using 
the comparative Ct method. Fold change calculations were normalized to the median Ct 
value of the healthy controls group. Statistical significance for Figure 3.2 and Figure 3.3 
were calculated using a Mann-Whitney (nonparametric) t-test. Statistical significance (p 
< 0.05) for the luciferase assay data shown in Figure 3.5 and Figure 3.6 was performed 
using a two-tailed paired t-test comparing percent RLU of the miR-NS control and each 
miRNA group. RLU values were normalized to the protein concentration of the lysates 
and percent RLU was calculated. Percent RLU was calculated as follows: (average 
RLUmiRNA/ average RLUcontrol) x 100.  Statistical significance (p < 0.05) for Figure 3.7 
and Figure 3.8 was calculated with a Wilcoxon (nonparametric) matched pairs test. All 
statistical analyses were calculated using GraphPad Prism 4 Software (GraphPad 
Software). 
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Results  
Differentially Expressed miRNAs in the Naïve CD4 T cells of MS Patients are Predicted 
to Target and Inhibit the TGF Signaling Pathway 
In order to investigate differences in the CD4 T cells of MS patients and healthy 
individuals, we previously performed a miRNA profiling study on the naïve and memory 
CD4 T cells of individuals with MS and healthy donors (Guerau-de-Arellano, Smith et al. 
2011). We identified 85 differentially expressed miRNAs in the naïve CD4+CD45RA+ T 
cells of MS patients compared to healthy controls. Pathway analysis identified that 19 of 
the 85 dysregulated miRNAs were predicted to target and inhibit the TGF signaling 
pathway (Figure 3.1). However, in order to narrow the scope of this study, my initial 
experiments were limited to investigating the upregulated miRNAs predicted to target 
TGFR1, TGFR2, SMAD2, and SMAD4. Additionally, we required that the miRNA 
meet an inclusion criterion of a fold-change (FC) greater than 5. The fold change values 
for the upregulated miRNAs that met the inclusion criteria are shown in Table 1. As a 
result of these findings, we hypothesized that the miRNAs differentially expressed in the 
naïve CD4 T cells of MS patients inhibit the TGF signaling pathway, resulting in 
decreased levels of their TGF-associated target genes. 
 
TGFR1 and SMAD4 Expression Levels are Reduced in the Naïve CD4 T cells of MS 
Patients  
Given that miRNAs can cause decreased in mRNA and protein levels, I performed two 
separate experiments to investigate if TGF signaling is decreased in the naïve CD4 T 
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cells of MS patients. To determine if mRNA levels of the TGF-associated genes were 
reduced in MS patients, real-time PCR was performed on the RNA from the naïve 
CD4
+
CD45RA
+
 T cells of treatment naïve MS patients (n = 22) and healthy controls 
(HC; n = 7). The RNA utilized for this experiment was from the same samples used in 
the miRNA profiling study.  This allowed us to analyze whether the set of MS patients 
identified to have dysregulated miRNAs that were predicted to target the TGF signaling 
pathway also had lower expression of TGF-associated genes (TGFR1, TGFR2, 
SMAD2, and SMAD4). Of the four predicted genes evaluated, TGFR1 and SMAD4 
were significantly decreased in MS patients compared to HC (Figure 3.2). TGFR2 
trended towards a decrease in MS patients, but was not statistically significant (Figure 
3.2). Thus, TGFR1 and SMAD4 were the focus of my study. 
 
In order to determine if protein levels of TGFR1 and SMAD4 were also decreased, we 
performed flow cytometry on the Naïve CD4+CD45RA+ T cells from a selection of the 
previously analyzed MS (n = 14) and HC (n = 4) samples. Given that almost 100% of 
naïve CD4 T cells endogenously express TGFR1 and SMAD4, I analyzed the geometric 
MFI of each protein. This strategy allowed us to evaluate the amount of TGFR1 and 
SMAD4 on a per cell level basis and thus, determine if TGF signaling was reduced in 
MS patients. TGFR1 was not significantly decreased when comparing total MS patients 
compared to HC (Figure 3.3). However, when patients were grouped by their subtype of 
MS and compared to HC, TGFR1 protein levels were significantly decreased in the 
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SPMS patient (Figure 3.3). The protein levels of SMAD4 were significantly decreased in 
total MS patients compared to HC (Figure 3.3).  
 
Therefore, my graduate studies focused on the miRNAs predicted to target TGFR1 and 
SMAD4. The expression levels, represented as fold change, for the dysregulated miRNAs 
predicted to target TGFR1 and SMAD4 are shown in Figure 3.4. These data 
demonstrate that TGFR1 and SMAD4 levels are significantly decreased in the same MS 
patients who have differentially expressed miRNAs predicted to target the TGF 
signaling pathway.  
 
miRNAs Dysregulated in the Naïve CD4 T cells of MS Patients Directly Bind and 
Regulate TGFR1 and SMAD4 
In order to identify which miRNAs directly bind and potentially regulate their predicted 
target genes, TGFR1 and SMAD4, luciferase assays were performed. Both of these 
genes contain very large 3’UTRs and therefore, it was necessary to generate multiple 
fragments for the assay. These segments of the 3’UTRs of TGFR1 (Figure 3.5A) and 
SMAD4 (Figure 3.6A), which contain miRNA binding sites, were inserted into luciferase 
vectors and co-transfected into cos-7 cells with the appropriate individual miRNA. A 
reduction in luciferase activity would be indicative of miRNA regulation. miR-NS was 
used as a control to indicate the normal levels of luciferase activity. All of the miRNAs 
predicted to target TGFR1 were shown to cause a significant reduction in the relative 
light units (RLU) when co-transfected with the appropriate TGFR1 construct:miRNA 
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pairs (Figure 3.5B). All the miRNAs predicted to target SMAD4, except miR-18a, had a 
significant reduction in RLU (Figure 3.6B). These data indicate that the identified 
miRNAs, with the exception of miR-18a, can in fact bind their predicted target genes, 
suggesting that these miRNAs have the potential to modulate TGF signaling through 
their regulation of TGFR1 and SMAD4. As a result of these findings, we hypothesized 
that overexpression of miR-27b, miR-103, miR-128, miR-141, miR-212, miR-500, miR-
628-3p, miR-708, let-7a, let-7b, and let-7f in naïve CD4 T cells would result in decreased 
levels of TGFR1 and SMAD4. 
 
Overexpression of MS-Associated miRNAs Decrease TGFR1 and SMAD4 Levels 
Given that MS-associated miRNAs can directly bind and inhibit TGFR1 and SMAD4, I 
wanted to further verify that these miRNAs could directly regulate translation of these 
genes in naïve CD4 T cells. To determine if the TGF-targeting miRNAs could decrease 
these genes in naïve CD4 T cells, miRNAs were overexpressed in healthy donor PBMCs. 
PBMCs from healthy individuals, not MS patients since they already have altered 
miRNA levels, were transfected with single miRNAs or miRNAs in combination. 
Subsequently, flow cytometry was used to analyze the TGFR1 and SMAD4 levels in the 
naïve CD4
+
CD45RA
+
 T cells. TGFR1 and SMAD4 are constitutively expressed at high 
levels in approximately 100% of T cells. Therefore, to detect changes in protein levels on 
a per cell basis, I measured the mean fluorescence intensity (MFI) of these proteins.  
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Figure 3.7A illustrates the changes in TGFR1 levels following miRNA transfection for 
one individual PBMC sample. The quantification for this representative sample is shown 
in red in Figure 3.7B, as well as the changes for each miRNA in 15 PBMC samples. For 
TGFR1, 6 of the 7 miRNAs (miR-27b, miR-141, miR-500a, let-7a, let-7b, and let-7f) 
significantly decreased the MFI (Figure 3.7B).  Since we typically observed multiple 
dysregulated miRNAs in MS patients, I wanted to determine if having multiple miRNAs 
overexpressed augments changes in TGFR1 levels. In the last panel of Figure 3.7B, I 
demonstrate that a combination of miR-141, miR-500a and let-7b results in a more 
significant decrease in TGFR1 levels.  
 
Similarly, Figure 3.8A shows the effect of miRNA overexpression on SMAD4 levels for 
a single PBMC sample. This sample is represented in red in Figure 3.8B, as well as data 
for 14 additional samples. For SMAD4, 5 of the 8 miRNAs (miR-141, miR-212, miR-
500a, miR-628-3p, and miR-708) significantly decreased the MFI of SMAD4 (Figure 
3.8B). In the last panel of Figure 3.8B, I show that the overexpression of miR-103, miR-
212, and miR-708 in combination can have a synergistic effect, resulting in enhanced 
suppression of SMAD4. Overall, the changes in MFI demonstrated in Figures 3.7 and 3.8 
indicate that elevated levels of TGF-targeting miRNAs, especially in combination, can 
reduce the TGF signaling capacity of naïve CD4 T cells. Given that TGF signaling is 
required for the development of Tregs, the elevated expression of these miRNAs in MS 
patients’ naïve CD4 T cells suggests that these miRNAs play a role in the Treg defect 
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observed in MS patients. Therefore, we hypothesized that overexpression of these 
miRNAs in naïve CD4 T cells would suppress their capacity to differentiate into iTregs. 
 
Discussion 
When taken together, our findings demonstrate that TGF signaling genes are diminished 
in MS patients and suggest that the identified differentially expressed miRNAs may be 
responsible for the observed inhibition of TGF signaling genes. It is important to note 
that while we investigated 19 individual miRNAs predicted to target 4 genes of the TGF 
signaling pathway, there were other miRNAs among the 85 identified that were predicted 
to target this pathway. However, given the extensive list of differentially expressed 
miRNAs and target genes, we had to determine exclusion criteria throughout my work. In 
order to limit our initial miRNA list, we chose to only include statistically significant 
miRNAs that had a fold change greater than 5 when comparing MS patients and healthy 
controls. The miRNAs also had to be differentially expressed specifically in RRMS, since 
RRMS is the most common form of MS. Therefore, there are other miRNAs predicted to 
target the TGF signaling pathway that may contribute to the reduced levels of TGFR1 
and SMAD4.  
 
Additionally, other than the investigated target genes (TGFR1, TGFR2, SMAD2, and 
SMAD4), SMAD7 was also predicted to be targeted. For my graduate project, we 
decided to focus on the miRNAs that were upregulated, allowing for a more simplified 
and cohesive working hypothesis. If the miRNAs were upregulated, their targets were 
54 
 
predicted to be downregulated, thus resulting in diminished TGF signaling. Thus, we 
decided to not investigate the downregulated miRNAs predicted to target SMAD7. 
However, this does not mean that effect of miRNAs on SMAD7 expression should not be 
addressed, but this will be the focus of future studies. TGFR2 may also be of interest in 
future studies. While the reduction in this gene was not statistically significant, its levels 
trended towards a decrease in MS patients. When looking at the data, it is evident that the 
range of TGFR2 levels is very diverse within the sampled MS population. The lack of 
significance could merely be a result of insufficient sample numbers to account for this 
dispersal of TGFR2 levels in the tested individuals. 
 
The most significant decrease of TGFR1 and SMAD4 in the naïve CD4 T cells of MS 
patients was observed at the mRNA level. Several factors may contribute to the statistical 
differences in mRNA and protein levels. Due to the limited quantities of cells available 
from the individuals used in the initial miRNA profiling study, I was only able to include 
4 HC samples. Increasing HC numbers would allow for a more accurate representation of 
the healthy population and could potentially magnify the difference observed. 
Additionally, lack of flow antibodies able to detect TGFR1 on the surface of cells 
confined me to using a suboptimal alternative. The TGFR1 antibody used was an 
unconjugated polyclonal antibody against an epitope within the C-terminal cytoplasmic 
domain of TGFR1, which poses a couple concerns. Given that the antibody is 
polyclonal, it has disadvantages when applied to flow cytometry, such as excessive 
background fluorescence due to non-specific binding and inaccurate quantification due to 
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the binding of multiple epitopes on the same protein. Additionally, levels of TGFR1 
measured with this intracellular antibody may not be representative of the amount of 
active TGFR1 available on the surface of the cells to bind TGF and promote signaling. 
Alternative methods for future studies could include isolation of protein from the naïve 
CD4 T cells of MS patients for the detection of extracellular TGFR1 epitopes via 
western blotting. However, similar issues of non-specific binding and misrepresentation 
of active TGFR1 levels may occur my primary method for determining if TGF 
signaling genes are decreased in MS patients, real-time PCR, is highly sensitive and 
indicate that both TGFR1 and SMAD4 are reduced in MS patients compared to healthy 
individuals. Despite possible protein detection sensitivity issues, the protein levels do 
appear to support my conclusions drawn from the mRNA data. These findings provided 
justification for focusing my studies on miRNAs specifically predicted to target TGFR1 
and SMAD4.  
 
My further studies with these genes shown in Figures 3.5 -3.8 demonstrate that most of 
the miRNAs predicted to target the TGF signaling pathway are capable of directly 
binding and inhibiting TGFR1 and SMAD4 expression. This was first demonstrated in 
the luciferase assays. The extensive size of the 3’UTRs of these genes made generating 
the luciferase constructs very complex. The initial challenge was dividing the 3’UTR in 
way that retained all the necessary miRNA binding sites, while keeping the number of 
segments minimal and their length optimal. It took many attempts to design primers that 
were efficient in exclusively amplifying the desired gene segments. Additionally, having 
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used a single enzyme for the digestions, the inserts could either bind to the plasmid in the 
3’ to 5’ or 5’ to 3’ direction. Gel electrophoresis only allowed us to identify whether the 
insert was the correct size, not if the insert was in the correct orientation. Therefore, I had 
to perform secondary verifications using DNA sequencing. 
 
Additionally, as a result of complications with my cos-7 cell cultures, I switched to an 
alternative cell line. I chose RAW 264.7 macrophages because they are hearty adherent 
cells, which were previously transfected in the lab with success. Additionally, there were 
reports documenting their successful application in Promega luciferase assays. However, 
I was continually observing very low, almost undetectable, RLU values. Despite several 
attempts to optimize culture conditions according to published protocols, the assay failed 
to work. Upon additional thought and research, I discovered the key detail that I was 
missing. The pGL3 vector contains Simian Virus 40 (SV40) promoter and enhancer 
regions.  Engagement of these regions with SV40 T antigen promotes vector replication, 
which can result in enhanced light detection. Given that RAW cells are not infected with 
SV40 there is not SV40 T antigen available in these cells. Interestingly, SV40 is 
commonly found in monkeys, the origin of cos-7 cells. Therefore, repeating the luciferase 
assays in cos-7 cells containing SV40 T antigen resulting in the production of detectable 
RLU levels, and useable data. Successful competition of these assays allowed me to 
determine which miRNAs did not regulate their predicted target genes, and thus allowed 
me to exclude miR-18a from future experiments, further focusing my work.  
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Overall the luciferase assays were essential for confirming the miRNA and target gene 
interactions and promoting further investigation. However, the assay is very artificial in 
terms of having to use cell lines versus primary cells. Additionally, the effect of miRNAs 
on protein levels of TGFR1 and SMAD4 is not directly established. Therefore, a more 
biologically relevant experiment was necessary, thus driving the miRNA transfection 
experiments in Figures 3.7 and 3.8.  Given the challenges caused by human variation and 
the control provided in murine models, I initially performed the same miRNA 
transfection experiments in wild-type B10.Pl mice. However, unlike later studies with 
human PBMCs, I did not consistently observe changes in the TGF signaling genes when 
the various miRNAs were overexpressed. While doing these experiments, I was 
subsequently doing the miRNA mapping for the luciferase assays. I discovered that while 
the miRNAs themselves are highly conserved among mice and humans, their binding 
sites are not. This was an extremely important fact to take into account when planning 
several of my other experiments, and drove me to perform most of my experiments in 
human PBMCs.  
 
Having to use PBMCs proved beneficial in that it was more biologically relevant, given 
that initial observations were made in the PBMCs of MS patients and healthy donors. For 
the miRNA transfection studies, we elected to use healthy donor PBMCs rather than MS 
patient PBMCs. Our rationale was that MS patients typically already have elevated levels 
of multiple miRNAs, making dissecting the effect of an individual miRNA difficult.  
Therefore, by overexpressing miRNAs in healthy PBMCs, we were able elucidate the 
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effect of individual miRNAs and mirror specific patterns that we observe in MS patients 
in a controlled setting. 
 
Additionally, there were several technical benefits to my PBMC transfection 
experiments. By using flow cytometry, I was able to look at the effect of overexpressing 
individual miRNAs directly on TGFR1 and SMAD4 expression levels. Importantly, I 
was able to assess the levels of these proteins specifically in naïve CD4 T cells on a per 
cell level basis, allowing me to observe changes in our primary cell of interest. 
Additionally, we chose miRNAs that are double-stranded RNAs designed to mimic 
endogenous, mature miRNAs. By being double-stranded, they require the cells own 
machinery to process it and load it into the RISC complex. In order to allow time for the 
miRNA machinery to work, I waited 48 hr after transfection before analyzing the cells. I 
also chose a 48 hr time point because SMAD4 is a very long-lived endogenous proteins, 
with a half-life over 12 hr. All of the described advantages to this method provided us 
with a biologically relevant model to use in future studies. Therefore, our next objective 
was to use this model to address our hypothesis of whether the overexpression of the 
TGF targeting miRNA has an effect on the development of iTregs. 
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Figure 3.1 Differentially expressed miRNAs in the naïve CD4 T cells of MS patients are 
predicted to target the TGFβ signaling pathway. 
 
A TaqMan® miRNA profiling array was performed on the naïve CD4+CD45RA+ T cells 
of healthy controls (HC; n = 16) and MS patients (MS; n = 22). Of the 85 differentially 
expressed miRNAs, 19 miRNA with a fold change >5 were predicted to target the TGFβ 
signaling pathway. The miRNAs are color matched with their predicted targets (TGFβR1, 
green; TGFβR2, light green; SMAD2, yellow; SMAD4, orange; and SMAD7, light blue). 
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Figure 3.2 TGFβR1 and SMAD4 mRNA is significantly decreased in the naïve CD4 T 
cells of MS patients. 
 
TaqMan
®
 real-time PCR performed on the naïve CD4+CD45RA+ T cells of MS patients 
(RRMS, n = 12; SPMS, n = 5; and PPMS, n = 5) and healthy controls (HC; n = 7). Fold 
Change (FC) was calculated and normalized relative to median Ct of the HC group. 
Statistical significance was calculated with a Mann-Whitney (nonparametric) t-test 
comparing HC to each MS group (*, p ≤ 0.05; **, p ≤ 0.01; and ns, p > 0.05). Mean FC 
for each sample group is represented by a line in each column. TGFβR1 and SMAD4 
were found to be significantly decreased (p < 0.05) in MS patients. 
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Figure 3.3 TGFβR1 and SMAD4 proteins are decreased in the naïve CD4 T cells from 
select MS patient groups. 
 
Flow cytometry was performed on the naïve CD4+CD45RA+ T cells of MS patients 
(RRMS, n = 6; SPMS, n = 4; and PPMS, n = 4) and healthy controls (HC; n = 4). 
Geometric MFI was measured and statistical significance was calculated with a Mann-
Whitney (nonparametric) t-test comparing HC to each MS group (*, p ≤ 0.05 and ns, p > 
0.05).  Mean geometric MFI for each sample group is represented by a line in each 
column. TGFβR1 and SMAD4 were found to be significantly decreased (p < 0.05) in 
SPMS patients. 
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Figure 3.4 TGFβR1 and SMAD4 targeting miRNAs are upregulated in the naïve CD4 T 
cells of MS patients.  
 
For the miRNAs predicted to target TGFβR1 and SMAD4, fold change (FC) was 
calculated and normalized relative to the geometric mean Ct of the HC group. Mean FC 
for each sample group is represented by a line. Statistical significance (p < 0.05) was 
calculated with a parametric Limma test. P values for the comparisons of the HC (n = 16) 
and MS (n = 22) groups are shown. 
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Figure 3.5 Differentially expressed miRNAs directly bind and regulate TGFβR1.  
 
Luciferase assays were conducted using pGL3 vector constructs containing segments of 
the 3’UTR of TGFβR1. (A) The 3’UTR of TGFβR1 was amplified as two separate 
segments. The miRNA binding sites within each segment are noted. (B) Significance was 
calculated using an unpaired t-test comparing the relative luciferase units (RLU) of the 
miR-NS control and individual miRNA groups (**, p ≤ 0.01; ***, p ≤ 0.001; and **** p 
≤ 0.0001). All of the miRNAs predicted to target TGFβR1 caused a reduction in RLU. 
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Figure 3.6 Dysregulated miRNAs directly bind and regulate SMAD4.  
 
Luciferase assays were conducted using vector constructs containing 3’UTR segments of 
SMAD4. (A) The 3’UTR of SMAD4 was divided into four separate segments. The 
miRNA binding sites within each segment are noted. (B) Significance was calculated 
using an unpaired t-test comparing the RLU of the miR-NS control and each miRNA 
groups (**, p ≤ 0.01; ***, p ≤ 0.001; and **** p ≤ 0.0001). All of the miRNAs tested, 
except miR-18, SMAD4 reduce RLU. 
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Figure 3.7 Overexpression of TGFβ-targeting miRNAs reduces TGFβR1 expression.  
 
Individual or combinations of miRNAs predicted to target TGFβR1 were transfected into 
PMBCs from healthy controls. Flow cytometry was used to analyze changes in TGFβR1 
levels. (A) Flow plots representative of data from a single individual. (B) Each line 
represents a unique PBMC sample (n = 15) with the red line representing the data in 
panel A. The geometric mean florescence intensity (MFI) was measured and compared 
between miR-NS and individual or combined miRNA groups. A Wilcoxon matched pairs 
test calculated significance (p < 0.05). 
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Figure 3.7  
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Figure 3.8 Overexpression of TGFβ-targeting miRNAs reduces SMAD4 expression.  
 
Individual or combinations of miRNAs predicted to target SMAD4 were transfected into 
PMBCs from healthy controls. Flow cytometry was used to analyze changes in SMAD4 
levels. (A) Flow plots representative of data from a single individual. (B) Each line 
represents a unique PBMC sample (n = 15) with the red line representing the data in 
panel A. The geometric mean florescence intensity (MFI) was measured and compared 
between miR-NS and individual or combined miRNA groups. A Wilcoxon matched pairs 
test calculated significance (p < 0.05). 
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Figure 3.8  
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Table 1. Select miRNAs upregulated in the naïve CD4 T cells of MS patients. 
miRNA Fold Change P value 
hsa-miR-18a 16.35 5.45E-05 
hsa-miR-27b 5.66 4.09E-03 
hsa-miR-103a 8.41 6.24E-04 
hsa-mIR-128 
 
20.76 8.07E-06 
hsa-miR-141 5.86 1.27E-03 
hsa-miR-212 8.52 5.20E-04 
hsa-miR-423-5p 15.96 3.19E-03 
hsa-miR-500 14.26 2.40E-03 
hsa-miR-505* 10.58 2.13E-03 
hsa-miR-532-5p 
32-5p 
14.75 2.64E-04 
hsa-miR-660 191.66 3.41E-06 
hsa-miR-let-7a 88.38 1.45E-03 
hsa-miR-let-7b 8.52 1.23E-03 
hsa-miR-let-7f 60.78 4.11E-04 
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Chapter 4: Overexpression of TGFβ-Targeting miRNAs Decrease Treg Development 
 
Introduction 
One of the mechanisms hypothesized to propagate MS pathology is an inflammatory 
attack driven by activated myelin-specific T cells that are targeting the CNS. 
Interestingly, these autoreactive T cells are found in healthy individuals as well (Sun, 
Olsson et al. 1991, Lovett-Racke, Trotter et al. 1998, Pelfrey, Rudick et al. 2000, 
Crawford, Yan et al. 2004), suggesting that MS patients lack the normal regulatory 
mechanisms needed to suppress such immune responses. One of the main elements of 
regulation that is absent in MS patients is a fully functional Treg population. The Tregs of 
MS patients have diminished suppressive effect on the autoimmune response against 
myelin-specific T cells (Viglietta, Baecher-Allan et al. 2004, Haas, Hug et al. 2005, 
Kumar, Putzki et al. 2006) and have low expression of the transcription factor FoxP3 
(Huan, Culbertson et al. 2005, Venken, Hellings et al. 2008), which is required for the 
development and function of Tregs (Fontenot, Gavin et al. 2003, Hori, Nomura et al. 
2003, Khattri, Cox et al. 2003, Fontenot, Rasmussen et al. 2005).  
 
TGFβ has also been shown to be critical for maintaining the differentiation and 
suppressive capacity of Tregs, through its role in promoting FoxP3 transcription (Chen, 
Jin et al. 2003). Interestingly, TGFβ1 and TGFβ receptor deficient mice develop a multi-
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organ autoimmune disease similar to humans with mutated FoxP3 genes (Shull, Ormsby 
et al. 1992, Kulkarni and Karlsson 1993, Gorelik and Flavell 2000, Bennett, Christie et 
al. 2001, Brunkow, Jeffery et al. 2001, Wildin, Ramsdell et al. 2001). These findings not 
only suggest a relationship between TGFβ and FoxP3, but also provide a link between 
FoxP3/TGFβ deficiencies and autoimmunity. The uncontrolled autoimmunity in these 
mice has been attributed to a defect in their Tregs. These mice exhibit a Treg phenotype 
with normal numbers, diminished suppressive effect, a limited TCR repertoire, and low 
FoxP3 expression, mirroring observations in MS patients. While these observations 
suggest a connection between inhibition of TGFβ signaling and Treg defects, the 
mechanisms by which Tregs become defective in MS have not yet been determined. 
Understanding the relationship between T cell driven autoimmune responses and the 
dysregulation of Tregs in MS patients can provide valuable understanding of the cause 
and course of this disease. 
 
As demonstrated in Chapter 3, several of the miRNAs identified as dysregulated in the 
naïve CD4 T cells of MS patients are capable of suppressing TGFβ signaling. Given the 
importance of TGFβ signaling in Treg development and the Treg defect observed in MS 
patients, the logical next step was to investigate the ability of these TGFβ-targeting 
miRNAs to impede Treg development. Therefore, the objective of aim 2 was to identify 
which TGFβ-targeting miRNAs alter the development of iTregs in vivo. The working 
hypothesis was that over expression of miRNAs that target specific genes known to 
promote TGFβ-pathway signaling would cause a decrease in signaling and attenuate the 
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development of iTregs. The rationale for the work described in Chapter 4 was that the 
identification of specific miRNAs capable of inhibiting Treg induction would potentially 
enhance understanding of the mechanisms underlying the Treg defect seen in MS 
patients. 
 
Materials and Methods 
miRNA Transfection 
PBMCs were obtained from the American Red Cross and isolated as described in Chapter 
2. PBMCs from healthy individuals, as defined by the Red Cross, were transfected with 
individual miRNA mimics (miR-NS, miR-27b, miR-103a, miR-128, miR-141, miR-212, 
miR-500a, miR-628-3p, miR-708, let-7a, and let-7b; GE Healthcare Dharmacon) or 
miRNA mimics in combination (miR-103/212/708; miR-141/500a/let-7b; miR-128/628-
3p/let-7ab). miR-NS was included as a negative control for each individual PBMC 
sample transfected. Source leukocytes were obtained and kept at room temperature. 
PBMCs were isolated from the source leukocytes within 24 hr of donation. Cells were 
plated, transfected, and cultured as described in Chapter 2.  
 
Treg Induction 
After the 48 hr transfection, cells were washed, counted, and cultured according to the In 
Vitro Treg Induction protocol in Chapter 2. Suboptimal iTreg culture conditions were 
used to avoid saturating the naïve CD4 T cells and masking differences in Treg induction.  
Flow Cytometry 
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After the 48 hr incubation, the miRNA transfected PBMCs were analyzed for Treg 
induction via flow cytometry as described in Chapter 2. In order to look at differentiation 
of Tregs from naïve CD4 T cells, the PBMCs were stained with the surface antibodies 
human anti-CD4-PB (BD Biosciences), human anti-CD45RA-APC (BioLegend), and 
human anti-CD25-FITC (BD Biosciences). The cells were also stained with the 
intracellular antibody human anti-FoxP3-PE (eBioscience) and the primary antibody anti-
human TGFβR1 V 1-22 (Santa Cruz). When analyzed, the cells were first subgated on 
naïve CD4 T cells (CD4+CD45RA+). The Tregs were defined as the 
CD4+CD45RA+CD25
hi
FoxP3+ cells. 
 
IL-10 Enzyme-Linked Immunosorbent Assay (ELISA) 
Supernatants were collected from the iTreg cultures and analyzed for IL-10. ELISA was 
performed as follows: purified rat anti-human IL-10 capture antibody (BD Biosciences) 
was diluted to 2 µg/ml in NaHCO3 (0.1M; pH 8.2); Immulon II 96-well plates were 
coated with 50 µl of diluted antibody and incubated at 4 °C overnight; plates were 
washed twice with 200 µl PBS/Tween 20; 200 µl 1% BSA/PBS was added to each well 
and incubated at room temperature for 2 hr; plates were washed twice with 200 µl 
PBS/Tween 20; 100 µl diluted recombinant human IL-10 standards (2 ng/ml to 0 ng/ml) 
was added to triplicate wells; 100 µl supernatant was added to duplicate wells; plates 
were incubated at 4 °C overnight; plates were washed four times with PBS/Tween 20; 
biotinylated anti-IL-10 antibody (BD Biosciences) was diluted to 1 µg/ml in 1% 
BSA/PBS; 100 ul of diluted detection antibody was added to each well; plate was 
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incubated for 60 min at room temperature; plate was washed six times with PBS/Tween 
20; avidin-peroxidase was diluted to 2.5 µg/ml in 1% BSA/PBS; 100 µl diluted avidin-
peroxidase was added to each well; plate was incubated for 30 min at room temperature; 
plate was washed eight times with PBS/Tween 20; 100 µl of H2O2/ABTS substrate was 
added to each well; plate developed for approximately 10 min at room temperature in the 
dark; plates were read at OD 405 nm on a microplate reader. IL-10 concentrations were 
calculated from known standards of recombinant IL-10 protein (R&D Systems) and 
analyzed via SoftMax Pro Software (Molecular Devices). 
 
Statistical Analysis 
Statistical significance (p value < 0.05) for Figures 4.1 and 4.2 was calculated with a 
Wilcoxon (nonparametric) matched pairs test. All statistical analyses were calculated 
using GraphPad Prism 4 Software (GraphPad Software). For Figure 4.3, a non-parametric 
Pearson correlation test analyzed the degree of relatedness between the levels of IL-10 
and percent of iTregs generated. 
 
Results  
Overexpression of Individual TGF-Associated miRNAs Decrease Treg Development 
Given the dysregulation of TGFβ-targeting miRNAs in MS patients and the importance 
of TGFβ in Treg development, we wanted to determine if overexpression of these TGFβ-
associated miRNAs could decrease the differentiation of naïve CD4
+
CD45RA
+
 T cells 
into iTregs. PBMCs from healthy individuals were transfected with individual miRNAs 
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(miR-NS, miR-27b, miR-103, miR-128, miR-141, miR-500a, miR-628-3p, miR-708, let-
7a, let-7b, and let-7f). Following a 48 hr incubation, flow cytometry was used to analyze 
the percentage of naïve CD4 T cells (CD4+CD45RA+) that were able to differentiate into 
iTregs (CD25
hi
FoxP3+). Figure 4.1A illustrates the percentage of iTregs generated from 
one PBMC sample when the miRNAs are overexpressed individually. Analysis of a panel 
of PBMCs (n = 14-19) found that miR-27b, miR-103, miR-128, miR-628-3p, and miR-
708 significantly decreased iTreg development (Figure 4.1B, the sample shown in Figure 
4.1A is indicated by red line).  
 
Overexpression of TGF-Associated miRNAs in Combination Enhance Suppression of 
Treg Development 
Similar to MS patients, overexpression of a single TGFβ-targeting miRNA was not 
unusual in the healthy control population, as seen in Figure 3.4. However, unlike healthy 
individuals, we observed that MS patients typically had multiple TGF-targeting 
miRNAs overexpressed. Therefore, I tested combinations of miRNAs found to be 
overexpressed in the MS patients’ naïve CD4 T cells to determine if there may be a 
synergistic effect of the TGFβ-targeting miRNAs. I transfected three different miRNA 
combinations (miR-141/500/let-7b; miR-103/212/708; or miR-128/628-3p/let-7ab) 
observed in MS patients into PBMCs of healthy controls (HC) and evaluated for iTreg 
development. Figure 4.2A shows representative flow plots from a single PBMC sample 
that demonstrates an approximately 50% decrease in the percent of Tregs induced when 
miRNAs are overexpressed in combination. Analysis of a panel of PBMCs (n = 14-19) 
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found that all three combinations demonstrated highly significant reductions in iTregs 
(Figure 4.2B, the sample shown in Figure 4.2A is indicated by red line). In fact, miR-
141/500/let-7b, which had no significant effect individually on iTreg development, 
showed a significant decrease in combination, indicative of the synergistic effect. 
Similarly, the percent decrease in the other two miRNA combinations were more 
significant than the individual miRNAs, suggesting that the elevated expression of 
multiple TGFβ-targeting miRNAs in naïve CD4 T cells of MS patients diminishes their 
capacity to generate iTregs. 
 
IL-10 Production is not Inhibited in iTregs Generated from miRNA Transfected Naïve 
CD4 T Cells 
One of the ways in which Tregs function is by secreting anti-inflammatory cytokines 
which can act on other immune cells to dampen pro-inflammatory responses. To begin to 
address the functional status of the Tregs generated from naïve T cells overexpressing 
these miRNAs, IL-10 levels in the supernatants of the miRNA transfected iTregs were 
analyzed. Figures 4.3A-B demonstrates data from a single PBMC sample transfected 
with TGFβ-targeting miRNAs. When PBMCs were transfected with TGFβ-targeting 
miRNAs and cultured in iTreg conditions, overall Treg numbers were decreased (Figure 
4.3A), as were levels of secreted IL-10 (Figure 4.3B). However, I saw a positive 
correlation between the numbers of iTregs and levels of IL-10, indicating that the Tregs 
that did develop were able to produce normal levels of IL-10 (Figure 4.3C). These data 
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suggest that these miRNAs limit Treg development, but not their ability to produce the 
anti-inflammatory cytokine IL-10. 
 
Discussion 
When taken together, my findings demonstrate that the overexpression of TGFβ-targeting 
miRNAs can directly decrease the number of iTregs (CD4+CD25
hi
Foxp3+ cells) 
generated. While I have shown that IL-10 production does not appear to be altered in 
these cells, I think further investigation into the ability of these cells to secrete other anti-
inflammatory cytokines and suppress effector T cell proliferation is necessary. 
Importantly, my work is the first to link the enhanced negative regulation of the TGFβ-
signaling pathway by specific miRNAs to a reduction in Treg development, potentially 
explaining the Treg defect observed in MS patients. 
 
While straightforward in theory, the transfection experiments I performed proved to be 
challenging for several reasons. When I was initially designing these experiments, I chose 
Treg inducing conditions that were commonly described in the literature and proven to 
successfully generate iTregs. This protocol consisted of culturing PBMCs on anti-
CD3/CD28 coated plates in the presence of IL-2 (100 U/ml), tRA (2.5 nM), and TGFβ1 
(5 ng/ml). With these conditions, I was able to generate high percentages of iTregs. 
However, the differences in Treg induction between the control and miRNA groups were 
very modest. Typically, we would take this to mean that miRNAs were not as effective as 
hypothesized in inhibiting Treg development. However, I occasionally had PBMC 
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samples that demonstrated a significant decrease in the ability to generate iTregs when 
TGFβ-targeting miRNAs were overexpressed. Around the time that I was finishing up 
my twentieth PBMC sample with only marginal success, I attended a talk that 
demonstrated that high levels of anti-CD3/CD28 can mask differences in Treg 
development. After this talk, I thought about the possibility that I could be 
overstimulating my cells, allowing the cells to overcome any defects caused by the 
miRNAs. However, no difference was observed when I reduced the concentrations of 
anti-CD3/CD28 used to coat the plates. Fortunately, I attended another seminar by a 
guest lecturer who discussed the extreme sensitivity of Tregs to IL-2, demonstrating that 
Tregs can respond to levels of IL-2 100-fold lower than I was using. Interestingly, 
previous reports have demonstrated that reductions in Treg numbers are observed in 
TGFβ deficient mice post-natal, but that defect is eventually masked by Treg expansion 
via peripheral IL-2. I postulated that a similar effect was happening to my Tregs in vivo 
due to excessive amounts of IL-2 present in the culture. With these findings in mind, I 
performed several titration experiments with both IL-2 and TGFβ and eventually 
developed my current Treg induction protocol using only 1 U/ml IL-2 and 0.5 ng/ml 
TGFβ. Using these suboptimal conditions allowed me to observe differences between my 
control and miRNA conditions.  
 
In addition to the culture conditions, there was another flaw in my initial set of 
experiments. When I was calculating the percent of iTregs generated, I was gating on 
CD4+CD25
hi
FoxP3+ cells. This was problematic for a couple of reasons. In humans, 
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CD25 and FoxP3 are commonly accepted as Treg markers, yet they are not exclusive to 
Tregs. Both markers are transiently expressed during normal T cell activation. Therefore, 
it was possible that I was detecting T cells in this transient stage of activation that were 
not Tregs. Additionally, by gating on total CD4+ cells, I was not solely addressing 
whether overexpression of TGFβ-targeting miRNAs decreased differentiation of Tregs 
from naïve CD4 T cells. However, inadvertantly I noticed that CD45RA, an established 
marker for naïve/resting T lymphocytes, is not immediately down regulated when cells 
are stimulated. Rather, I was able to detect CD45RA on naïve CD4 T cells 72 hr after 
activation via flow cytometry, thus allowing me to detect the percentage of naïve 
CD4+CD45RA+ T cells that differentiated into iTregs. By switching to the suboptimal 
Treg protocol and the naïve T cell method of gating, I was able to observe significant 
differences in Treg development when select miRNAs were overexpressed.  
 
Additionally, as with any experiment using human samples, there was a lot of sample and 
experimental variation. This made pooling data extremely difficult. In order to ensure that 
the differences observed were not a consequence of this variation, I included a miR-NS 
control for every PBMC sample transfected, and used a matched pairs test to analyze the 
data. Additionally, I had to perform this experiment on multiple different PBMC samples 
to ensure accurate representation of the effect of miRNAs on Treg development in the 
population as a whole. High sample number was also necessary to observe differences 
between groups, since some individuals were non-responsive to increased miRNA levels. 
Some individuals responded opposite to what we would have expected. As evident in 
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Figure 4.1B, some samples made more iTregs when transfected with the various 
miRNAs. It is important to note that it was the same two individuals that demonstrated 
the strongest reverse responses to each miRNA. It is possible that there is an off target 
effect of the miRNAs that enhance Treg development in those individuals.  
 
Additionally, it is important to highlight the advantages our model has in terms of its use 
in mimicking miRNA profiles observed in MS patients. As mentioned in Chapter 3, by 
transfecting healthy PBMCs rather than MS patient PBMCs, we were able to look at the 
effects of individual miRNAs in a controlled setting. When I transfected the healthy 
PBMCs with specific TGFβ-targeting miRNAs, I observed a modest decrease in Treg 
induction. Interestingly, upregulation of a single miRNA is not exclusively observed in 
MS patients. As shown in Chapter 3, occasionally we would observe an increased level of 
TGFβ-targeting miRNAs in healthy individuals as well. While, outside the scope of our 
study, I think it would be interesting if a follow-up could have been done to investigate if 
any of the healthy donors from the initial profiling study demonstrating elevated miRNA 
levels eventually developed MS.  
 
While my data indicates that it is possible for an individual miRNA to have an effect on 
Treg development, the effect of miRNA dysregulation is much more robust when they 
are expressed in combination. This is important since most MS patients, unlike healthy 
individuals, demonstrate increased levels of multiple TGFβ-targeting miRNAs. 
Interestingly, miR-141, miR-500, and let-7b individually did not have significant effects 
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on Treg development. However, when I overexpressed these miRNAs in combination, as 
observed in MS patients, there was a significant reduction in iTregs. These findings 
suggest that there may be specific combinations of miRNAs, or a certain level of miRNA 
dysregulation that enhances the probability of developing a defect in Tregs, and thus 
potentially makes an individual more susceptible to developing MS. 
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Figure 4.1 Overexpression of TGFβ-targeting miRNAs decreases Treg induction. 
 
PBMCs from healthy controls were transfected with individual miRNA (0.05 M) and 
cultured in iTreg inducing conditions. The cells were analyzed using flow cytometry and 
iTregs (CD4+CD45RA+CD25
hi
Foxp3+) generated from naïve CD4 T cells were 
quantified. (A) Flow plots are representative data from a single individual. iTreg numbers 
are in red. (B) Each line represents a unique PBMC sample (n = 14-19) with the red line 
representing the data in panel A. A Wilcoxon matched pairs test comparing miR-NS and 
individual miRNA was used to calculate significance (p < 0.05).
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Figure 4.2 Overexpression of TGFβ-targeting miRNAs in combination exacerbate 
suppression of Treg induction. 
 
PBMCs from a healthy donor were transfected with miRNAs in combination (0.05 M 
total) and cultured in iTreg inducing conditions. The cells were analyzed using flow 
cytometry and iTregs (CD4+CD45RA+CD25
hi
Foxp3+) generated from naïve CD4 T 
cells were quantified. (A) Flow plots are representative data from the same individual 
shown in Figure 4.1A. iTreg numbers are in red (B) Each line represents a unique PBMC 
sample (n = 14-19) with the red line representing the data in panel A. A Wilcoxon 
matched pairs test comparing miR-NS and individual miRNA was used to calculate 
significance (p < 0.05).  
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Figure 4.3 IL-10 production is not inhibited in iTregs generated from miRNA transfected 
Naïve CD4 T cells. 
 
PBMCs from a healthy control (HC) were transfected with 0.05 μM of miRNA and 
cultured in iTreg inducing conditions. (A) iTregs (CD4+CD45RA+CD25
hi
Foxp3+) were 
analyzed using flow cytometry. (B) IL-10 was measured in the supernatants of the iTreg 
cultures demonstrated in panel A using ELISA. (C) A non-parametric Pearson correlation 
test analyzed the degree of relatedness between the levels of IL-10 and percent of iTregs 
generated. Representative of 4 independent experiments. 
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Chapter 5: Altered Expression of TGFβ-Targeting miRNAs is Associated with Reduced 
iTregs and Enhanced Susceptibility to CNS Autoimmunity 
 
Introduction 
Despite numerous genetic and epidemiological studies, few factors have been identified 
and confirmed as being linked to the cause of MS. While the cause is unknown, it is 
evident that MS patients appear to lack sufficient immune mechanisms capable of 
suppressing CNS inflammation. Interestingly, adult mice deficient in TGFβ signaling 
develop uncontrolled multi-focal autoimmunity, also indicative of a loss in immune 
regulation. Several in depth investigations have demonstrated that both MS patients and 
TGFβ-deficient mice exhibit a Treg phenotype with normal numbers, diminished 
suppressive effect, a limited TCR repertoire, and low FoxP3 expression (Vandenbark, 
Finn et al. 2001, Viglietta, Baecher-Allan et al. 2004, Haas, Hug et al. 2005, Kumar, 
Putzki et al. 2006). Under normal conditions, the TGFβ-signaling pathway promotes the 
expression of the critical transcription factor, FoxP3, thereby promoting the development 
and function of Tregs (Fontenot, Gavin et al. 2003, Hori, Nomura et al. 2003, Khattri, 
Cox et al. 2003, Fontenot, Rasmussen et al. 2005). Taken together, these studies suggest 
a potential link between the Treg defect observed in MS patients and TGFβ signaling 
deficiencies. However, no direct connection has been made between defects in TGFβ-
signaling and Treg development in MS patients.  
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As demonstrated in Chapters 3 and 4, several of the miRNAs identified as dysregulated 
in the naïve CD4 T cells of MS patients have the ability to inhibit TGFβ signaling and 
Treg development, especially when overexpressed in combination. Given that the initial 
observation of TGFβ-targeting miRNA dysregulation was made in MS patients, the 
logical next step was to look at Treg development and disease susceptibility in vivo.  
Therefore, the objective of aim 3 was to elucidate the effect of miRNA dysregulation on 
Treg generation and disease susceptibility in the context of CNS autoimmunity.  The 
working hypotheses were as follows: 1) the naïve CD4 T cells of MS patients have a 
reduced capacity to differentiate into Tregs and, 2) overexpression of TGFβ-targeting 
miRNAs in vivo would increase disease susceptibility via a reduced capacity to generate 
Tregs. The rationale for the work described in Chapter 5 was as follows: 1) the 
demonstration that MS patients have a defect in Treg development would verify the in 
vitro findings in the context of CNS disease, and 2) the identification of specific TGFβ-
targeting miRNAs that decrease Treg development and promote disease would 
potentially link miRNA dysregulation to enhanced disease susceptibility.  
 
Materials and Methods 
Human Subjects 
The MS patient (n = 10) and healthy control (n = 7) PBMCs in Figure 4.1 were obtained 
at the OSU MS Clinic. The samples were collected sequentially on two days from 
individuals who agreed to participate in the study following proper informed consent 
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protocol. There was no significant difference in age or gender between the groups. All of 
the MS patients were of the relapsing-remitting subtype. Of the MS patients, 5 were 
untreated (UMS) and 5 were currently on treatment (TMS). For the MS patients on 
treatment, 3 received Copaxone, 1 received Tysabri and 1 received Tecfidera. The 
healthy controls were a mix of individuals unrelated to MS patients (UHC) and first-
degree relatives of MS patients (1°HC).  
 
In Vitro Treg Induction 
PBMCs were isolated as described in Chapter 2, counted, and plated at a density of 1 x 
10
6
 cells/ml on 48-well plates coated with 1 µg/ml of human anti-CD3/CD28. The 
PBMCs were cultured according to the In Vitro Human Treg Induction protocol in 
Chapter 2.  
 
Flow Cytometry: Human iTregs 
After the 72 hr incubation, the PBMCs were analyzed for Treg induction via flow 
cytometry as described in Chapter 2. In order to look at differentiation of Tregs from 
naïve CD4 T cells, the PBMCs were stained with the surface antibodies human anti-CD4-
PB (BD Biosciences), human anti-CD45RA-APC (BioLegend), and human anti-CD25-
FITC (BD Biosciences). The cells were also stained with the intracellular antibody 
human anti-FOXP3-PE (eBioscience). When analyzed, the cells were first subgated on 
naïve CD4 T cells (CD4+CD45RA+). The Tregs were defined as the 
CD4+CD45RA+CD25
hi
Foxp3+ cells. 
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Mice 
B10.PL mice were bred in specific pathogen-free conditions at the OSU University 
Laboratory Animal Resources facility.  
 
In Vivo miRNA Injection 
Neonatal mice received an intraperitoneal (i.p.) injection via the inguinal route within 24 
hr of birth. Mice with injected with 5 µg of each miRNA mimic in combination (miR-
103/212/708, miR-141/500a/let-7b, or miR-128/628-3p/let-7ab). miR-NS injected mice 
were used as the control group. 
 
Flow Cytometry: Murine Tregs 
Cells were isolated from the spleen of mice 96 hr after i.p. injection with miRNAs. The 
resulting thymocytes and splenocytes were analyzed ex vivo for Tregs as described in 
Chapter 2. The cells were stained with the surface antibodies mouse anti-CD4-PcP 
(BioLegend) and mouse anti-CD25-PE (BD Biosciences). The cells were also stained 
with the intracellular antibody mouse anti-FoxP3-APC (eBioscience). When analyzed, 
the cells were first subgated on CD4+ T cells. The Tregs were defined as the CD4+ 
CD25
hi
FoxP3+ cells. 
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Experimental Autoimmune Encephalomyelitis (EAE) 
Neonatal mice were injected i.p. 24 hr after birth with 5 µg of each miRNA in 
combination (miR-103/212/708 or miR-141/500a/let-7b). The same mice received a 
second i.p. injection at 3 weeks of age with 10 µg of each miRNA (miR-103/212/708 or 
miR-141/500a/let-7b). Mice injected with miR-NS at 24 hr and 3 weeks were used as the 
control group. At 7 weeks, each mouse was immunized with 50 µl of MBPAc1-11 
peptide (4 mg/ml) emulsified in 50 µl of CFA supplemented with 100 µg of 
Mycobacterium tuberculosis. Mice were injected i.p. with 100 ng of pertussis toxin at the 
time of immunization and 48 hr later.  Mice were monitored for clinical signs and 
assessed according to the six-point EAE scoring scale (0-6): 0, no clinical disease; 1, limp 
tail; 2, moderate hind limb weakness; 3, severe hind limb weakness; 4, complete hind 
limb paralysis; 5, quadriplegia or moribund state; 6, death due to EAE.  
 
Statistical Analysis 
Statistical significance (p value < 0.05) for Figure 4.1 was calculated with an unpaired t-
test comparing the HC and MS patient groups. For Figure 4.3, statistical significance (p 
value < 0.05) was calculated using a Mann-Whitney test. 
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Results 
MS Patients and their First-Degree Relatives Demonstrate a Similar Reduced Capacity 
to Generate Tregs Ex Vivo  
In Chapter 4, I demonstrated that TGFβR1 and SMAD4-targeting miRNAs are capable of 
causing a reduction in Treg development. Given that our initial findings of dysregulated 
TGFβ-targeting miRNA were made in MS patients, we wanted to verify that naïve CD4 
T cells of MS patients have a diminished capacity to differentiate into iTregs. Although 
previous studies had demonstrated that Tregs taken directly ex vivo from MS patients had 
a decreased suppressive capacity, it had not been previously demonstrated that MS 
patients had a defect in the ability to generate iTregs. Naïve CD4+CD45RA+ T cells 
from MS patients and healthy controls (HC) were stimulated directly ex vivo with TGF, 
IL-2 and tRA on plate coated with anti-CD3/28 plates and analyzed for their capacity to 
become iTregs (CD25
hi
FoxP3+) via flow cytometry (Figure 5.1). Figure 5.1A depicts 
representative flow plots from a treated MS patient (TMS), an untreated MS patient 
(UMS), their first-degree relative (1°HC), and an unrelated healthy control (UHC). The 
initial comparison of the total healthy controls to the MS patients was not significant 
(Figure 5.1B). However, it appeared that the control population was bimodal in that there 
were high and low iTreg percentages in the HC cohort. Therefore, we reanalyzed the data 
by separating UHC and controls that were 1
o
HC of MS patients. We observed a 
significant difference in the percentage of iTregs generated from the MS patients 
compared to the UHC, but not the 1
o
HC (Figure 4.1B). In addition, comparison of the 
UMS and TMS patients indicated that treatment did not enhance or normalize iTreg 
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development. These data suggest that MS patients have a reduced capacity to generate 
iTregs from naïve CD4 T cells that may be genetically linked to their first-degree 
relatives who demonstrate a similar level of iTreg differentiation. These findings support 
and drive further investigation of our working hypothesis that there are genetic 
components, potentially miRNAs, which are dysregulated in MS patients and contribute 
to their defect in Tregs. 
 
Overexpression of TGFβ-Targeting miRNAs Enhance EAE Susceptibility and Severity 
Previous studies have shown that when TGFβ signaling is defective, autoimmunity can 
occur due to impaired Treg development (Shull, Ormsby et al. 1992, Kulkarni and 
Karlsson 1993, Gorelik and Flavell 2000). Given the data from these studies and our in 
vitro findings that MS patients have dysregulated miRNAs that can decrease TGFβ 
signaling and Treg development, we hypothesized that these miRNAs can result in 
enhanced disease susceptibility and severity when overexpressed. To test this hypothesis, 
I injected healthy neonatal mice with combinations of miRNAs (miR-141/500/let-7b and 
miR-103/212/708) within 24 hr of their birth, a critical window of time for Treg 
development. A second injection of the same miRNA combinations was administered at 
3 weeks of age to sustain the miRNA effects during development. The control group of 
mice was injected with miR-NS at both 24 hr and 3 weeks after birth. At 7 weeks, EAE 
was induced in these mice using a suboptimal immunization regimen so that the control 
mice would develop minimal EAE, allowing us to observe differences between the miR-
NS and miRNA combination groups. When injected with either combination of miRNAs, 
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mice had a significantly earlier onset and increased severity of disease (Figure 5.2). To 
determine if the enhanced EAE susceptibility could potentially be a result of defective 
Treg development, we looked at the Tregs from mice injected with the miRNA 
combinations. Splenocytes were isolated and analyzed for Tregs (CD4+CD25
hi
FoxP3+) 
via flow cytometry. Figure 5.3 shows representative flow data of one mouse from each 
miRNA group. This panel demonstrates that miRNA overexpression has the ability to 
cause decreased Treg development in vivo. However, due to variations in Treg frequency 
between litters, we have had limited success in showing statistical significance. However, 
we believe that the data as a whole suggest that, when overexpressed, the identified 
miRNAs can impair the TGFβ signaling pathway, dampen Treg development, and 
enhance susceptibility to CNS autoimmunity.  
 
Discussion 
Taken together, my findings demonstrate that dysregulation of TGFβ-targeting miRNAs 
can result in enhanced disease susceptibility in the context of CNS autoimmunity. 
Furthermore, as shown by the data in Figure 5.1, first-degree relatives of MS patients 
appear to have a similar decrease in their capacity to generate iTregs, suggesting a 
genetic component to the observed defect in Treg development. However, given the low 
sample number, additional studies are needed to verify these findings. It would be of 
interest to explore whether the Treg defect observed in the individuals from Figure 5.1 
was due to a dysregulation of TGFβ-targeting miRNAs. 
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My initial approach to addressing whether MS patients have a reduced capacity to 
generate iTregs involved using the same PBMCs as used in the miRNA profiling study. 
This would have potentially allowed me to directly correlate miRNA dysregulation with a 
reduction in Treg differentiation. However, when performing flow analysis on these cells 
I found the samples to have very low percentages of naïve CD4 T cells. I believe that the 
lack of healthy naïve CD4 T cells available to be differentiated into Tregs was a possible 
consequence of the freezing process used to store the cells. Therefore, in an effort to 
overcome this issue, we began using fresh PBMCs obtained from the OSU MS Clinic. 
The pitfall with utilizing new samples was that we lacked miRNA profiles for these 
individuals. Additionally, the volume of blood collected varied greatly between 
individuals, limiting the analyses that could be performed.  However, given that these 
samples were obtained from patients visiting the clinic, we had an increased likelihood 
that family members would accompany MS patients. It is important to note that we have 
obtained additional clinic samples other than those recorded in Figure 5.1. However, 
when analyzing the data, I noticed a significant increase in overall Treg generation after 
using a new aliquot of IL-2. This was an important finding in terms of designing my 
future experiments.  While this prevented us from being able to pool all our data, we were 
still able to calculate significance for the first group of samples obtained.  
 
Despite showing that first-degree relatives have a similar defect in their capacity to 
generate Tregs, we do not know why these individuals remain healthy. One possibility is 
that the first-degree relatives have MS, but are currently undiagnosed. The other and most 
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likely scenario is that the defects in Treg development observed in the first-degree 
healthy controls predisposes them to developing MS, but they have not been exposed to 
the necessary environmental triggers needed to initiate disease. While outside the scope 
of my study, investigating the miRNA profiles and Treg induction of MS patients and 
their first-degree relatives could provide valuable information regarding miRNAs as 
genetic risk factors for MS. 
 
The next step to investigate miRNAs in vivo was the use of the animal model for MS, 
EAE. However, several challenges emerged when I was designing the experiment. Since 
the miRNA binding sites are not completely conserved between mice and humans, I had 
to be selective when choosing which miRNAs to use. I chose miRNAs that had binding 
sites in murine SMAD4 and TGFBR1 genes. The miRNA combinations administered to 
mice were specifically chosen based on their in vitro success and presence in MS 
patients. Delivery of the miRNAs into mice was not without its own challenges.   
 
The time period surrounding birth is a critical window in the development of T cells. 
Therefore, we wanted to administer the miRNAs to mice as early in development as 
possible. Initially, we proposed to do tail vein injections on pregnant mothers with the 
hopes of delivering miRNAs to pups in utero. However, this form of delivery was 
stressful on mothers late in their pregnancies, and thus an alternative method was needed. 
To overcome this issue, we chose to deliver miRNAs to pups within 24 hr of their birth 
via i.p. injection. Again, this was also not without its complications. Given that neonatal 
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pups have very low fluid capacity in their peritoneal cavities, I observed severe injection 
site leakage. In order to prevent leakage, I tried, unsuccessfully, resting the pups on ice in 
order to limit their movement. After several attempts to prevent leakage, I was trained on 
how to deliver i.p injections through an inguinal route. This provided a longer injection 
route and less chance for immediate leakage, allowing the miRNA time to be absorbed. 
While this method has significantly improved injection efficiency, I still occasionally 
observe volume loss. This potentially could result in lower miRNA concentrations in 
those mice and diversity in the data.  
 
I also observed data diversity when looking at Tregs in mice 4 days after miRNA 
injection. After comparing several experiments, I noticed that there is a large amount of 
diversity in Treg frequency between different litters. The logical solution was to 
randomize litters. However, due to the fact that I was using neonatal mice, rejection of 
the pups by the mothers was a concern. In attempt to prevent this issue, we injected mice 
from the same litter with different miRNA combinations and marked their tails. Due to 
the foreign scent caused by the markings, the pups were frequently being rejected by their 
mothers. To completely overcome this issue, we chose to do timed pregnancies. These 
pregnancies involved priming cages with breeder males, exposing females to the same 
cages, and subsequently housing the male and multiple female breeders together for 24 
hr.  We did this with the hopes that multiple females would get pregnant and give birth at 
the same time, allowing us to randomize litters. While this approach has been moderately 
successfully, I believe that litter diversity is still an issue. When analyzing the data, I 
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observed heterogeneity among mice within the same miRNA group. I believe this could 
still be an artifact of litter variation. I am currently attempting randomized injections 
within the same litter, using tattoo ink to marker the pups. To avoid rejection, I plan to 
tattoo the mothers during pregnancy to acclimate them to the scent of the ink.   
 
Despite the pitfalls of neonatal i.p. injections, we were able to limit injection site leakage 
and maternal rejection, allowing us to use these mice for further in vivo experiments. The 
top priority was to induce EAE in these mice with the hypothesis that they would have 
earlier onset of disease and increased disease severity. Since we were looking for 
increases in disease severity, we had to modify our existing EAE protocol to be 
suboptimal. Consequently, our control mice developed mild disease allowing us to 
observe increases in disease severity in the other miRNA groups. EAE experiments have 
allowed us to test miRNA combinations commonly observed in MS patients as potential 
risk factors for developing CNS autoimmunity. I think it is important for us to elucidate 
the effect of individual miRNAs in vivo, in order to determine if the miRNAs are having 
a synergistic effect as observed in the in vitro miRNA transfection studies.  I believe that 
this would facilitate identification of the miRNAs with the most significant effect on the 
pathogenesis and susceptibility of MS. Despite experimental challenges, our ex vivo and 
in vivo data support our hypothesis that miRNAs are regulators of TGFB signaling, 
suppressors of Treg induction, and contributors to disease susceptibility.  
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Figure 5.1 MS patients and their first-degree relatives demonstrate a similar reduced 
capacity to generate Tregs ex vivo.  
 
Fresh PBMCs were collected sequentially from MS patients and healthy controls (HC) 
and iTregs were generated simultaneously from both populations. (A) Representative 
plots of an unrelated HC (UHC), a HC who is the first-degree relative of an MS patient 
(1
o
HC), an untreated MS patient (UMS), and a treated MS patient (TMS) are shown. (B) 
The differentiation of naïve CD4 T cells into iTregs (CD4+CD45RA+CD25
hi
Foxp3+) 
was compared between total HC (n = 7) and MS (n = 10) groups, using an unpaired t-test. 
There was no significant difference between the HC and MS patients. There was a 
significant difference between the UHC and MS patients, but not the 1
o
HC and MS 
patients. 
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Figure 5.2 Altered expression of TGFβ-targeting miRNAs is associated with 
susceptibility to CNS autoimmunity. 
 
Mice were i.p. injected 24 hr and 3 wk after birth with miR-NS (n = 4; incidence 2/4), 
miR-103/212/708 (n = 9; incidence 8/9), or miR-141/500a/let-7b (n = 4; incidence 4/4). 
EAE was induced using suboptimal conditions, and disease course was monitored for 4 
wk. A Mann-Whitney test calculated significance (p < 0.05). Both miRNA combination 
groups exhibited earlier onset and significantly increased disease severity. Representative 
of 3 independent experiments. 
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Figure 5.3 Altered expression of TGFβ-targeting miRNAs is potentially associated with 
reduced iTregs development. 
 
Mice were i.p. injected 24 hr after birth with miR-NS, miR-103/212/708, or miR-
141/500a/let-7b, or miR-128/628-3p/let-7ab. Splenocytes were isolated and analyzed for 
frequency of Tregs (CD4+CD25
hi
Foxp3+) via flow cytometry. Representative flow plots 
are shown for one mouse from each miRNA group. When comparing miRNA 
combination groups to miR-NS control, statistical significance was not observed.  
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Chapter 6: Discussion 
 
MS is a devastating disease that affects approximately 2.5 million people worldwide 
(Hersh and Fox 2010). While the pathology of the disease is not completely understood, 
it is characterized by inflammation, demyelination, and neurodegeneration in the CNS. 
Depending on the location and severity of damage within the CNS, patients diagnosed 
with MS suffer from a wide range of neurological symptoms such as pain, coordination 
impairment, cognitive changes, and emotional distress. Unfortunately, MS is the leading 
cause of non-traumatic disability in young adults, with diagnosis typically occurring 
between the ages of 20-40. Given the unpredictable and progressive nature of the disease, 
diagnosis with MS can greatly impact a patient's quality of life from an early age, 
threatening their autonomy and life planning. Currently, there is no cure for MS, and 
available treatments are limited, with only 1 of 12 DMTs indicated for SPMS and none 
indicated for PPMS, resulting in minimal chance for recovery especially in patients with 
progressive forms of the disease. Studies have demonstrated early use of DMTs in 
patients presenting with a CIS have a delayed conversion to CDMS (Jacobs, Beck et al. 
2000, Comi, Filippi et al. 2001, Kappos, Polman et al. 2006, Comi, Martinelli et al. 2009, 
Miller, Wolinsky et al. 2014). Therefore, diagnosis of patients early during the disease 
process while treatments are available is essential for delaying progression of the disease. 
However, diagnosis is challenging, as there is no single test for MS. Additionally, despite 
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the ability of existing drugs to slow down disease progression, the eventual worsening of 
symptoms is inevitable. Identification of individuals susceptible to developing MS may 
allow these patients to be proactive by submitting to routine screening and to prepare 
themselves for possible diagnosis. Therefore, I believe that research aimed at the 
identification of novel biomarkers and therapeutic targets is imperative for understanding 
disease activity, measuring treatment efficacy, and stopping disease progression.  
 
Both genetic and environmental studies have attempted to find causal biomarkers 
associated with MS, but identification of single markers with high sensitivity and 
specificity has been limited at best. For instance, genome-wide association studies 
(GWAS) have identified HLA-DRB1*1501 as a genetic marker for individuals with high 
risk to developing MS (Haegert and Marrosu 1994); however, this marker lacks 
sensitivity. This overall lack of success potentiates the need for innovative strategies for 
elucidating factors of disease susceptibility. Additionally, the complex nature of the 
disease makes treatment discovery and selection challenging. Given that both beneficial 
and adverse responses vary among MS patients, modification of treatment plans is often 
necessary. However, the current methods for treatment selection primarily rely on trial 
and error, with no means of predicting whether a patient will respond to a particular 
therapy prior to prescription. In order to enhance personalized therapeutic strategies, it is 
necessary to identify predictive markers for treatment response. At the very least, markers 
indicative of treatment efficacy are needed to allow for immediate adjustment in 
treatment if a patient is a non-responder. However, these are long-term and big picture 
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goals, and at this time, any insight into the mechanisms underlying the differential 
immune responses observed in MS patients would enhance the field's understanding of 
this multi-factorial disease. 
 
To this end, my lab began investigating the potential of miRNAs as biomarkers for MS. 
In recent years, miRNAs have emerged as important regulators that affect various 
biological processes. Even more recently, studies have begun to successfully show the 
clinical applications of miRNAs in various diseases such as cancer and rheumatoid 
arthritis (Lu, Getz et al. 2005, Calin and Croce 2006, Pers and Jorgensen 2013, Redova, 
Sana et al. 2013). In addition, the accessibility and relatively low number of miRNAs 
make them ideal potential biomarker candidates. In contrast to the MS studies performed 
by other labs looking at miRNA levels in total PBMCs, we specifically looked at miRNA 
expression in specific cellular subsets within the blood.  Given that MS is thought to 
involve a misdirected attack against the CNS mediated by myelin-specific T cells, the lab 
chose to specifically analyze the CD4 T cells of MS patients and healthy individuals. It is 
important to note that both memory and naïve CD4 T cells were profiled. While there is 
no direct evidence from MS patients, we believe that naïve CD4 T cells are unaffected by 
disease as they have not encountered antigen and experienced activation. To address this 
question, my lab previously performed a miRNA profiling study on the naïve CD4 T 
cells from mice with EAE and their non-EAE littermates. There were very few 
differences in miRNA levels between the EAE and non-EAE groups, and no differences 
were observed in miRNAs found differentially expressed in the MS patients’ naïve CD4 
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T cells. Therefore, it is unlikely that inflammation is causing the miRNA changes in 
naïve CD4 T cells in MS patients. Thus, we primarily focused on miRNA data from the 
naïve CD4 T cells with the aim of identifying differences in MS patients that were 
endogenous, rather than consequences of disease. With this rationale in mind, 85 
miRNAs were identified as being differentially expressed in the naïve CD4 T cells of MS 
patients, and analysis began to explore their potential role in the patholophysiology of 
MS. I highlight these findings and rationale because they served as the foundation for my 
graduate research, and were taken into account when analyzing the potential importance 
of my work. 
 
Further analysis of the profiling data revealed 19 differentially expressed miRNAs 
predicted to target genes of the TGFβ signaling pathway (TGFβR1, TGFβR2, SMAD2, 
and SMAD4), which were potentially capable of inhibiting TGFβ signaling (Figure 3.1). 
This possible connection of the identified miRNAs to TGFβ signaling in naïve CD4 T 
cells was of interest to the lab because TGFβ is known to be essential for the 
differentiation and function of Tregs (Yamagiwa, Gray et al. 2001, Zheng, Gray et al. 
2002, Chen, Jin et al. 2003). Interestingly, Tregs have the ability to directly suppress 
autoreactive T cells, a population of cells that appears to lack regulation in MS patients. 
These uncontrolled autoreactive T cells are hypothesized to be one of the main 
contributors to the excessive inflammation observed in individuals with MS. One of the 
main elements of regulation that is lacking in MS patients is a fully functional Treg 
population. The Tregs of MS patients have diminished suppressive effect on the 
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autoimmune response promoted by myelin-specific T cells (Viglietta, Baecher-Allan et 
al. 2004, Haas, Hug et al. 2005, Kumar, Putzki et al. 2006). Even though the effect of 
dysfunctional Tregs has been partially elucidated, the mechanism by which Tregs become 
defective and their exact role in MS pathogenesis have not yet been determined. 
Importantly, a link between a disruption of the TGFβ signaling pathway and the Treg 
dysfunction in MS patients has not previously been established. Additionally, the 
miRNAs identified in my studies have not previously been defined to play role in the 
development of Tregs or CNS autoimmunity. Therefore, my project provided an 
innovative strategy for identifying potential mechanisms for the Treg defects observed in 
MS patients. 
 
Before discussing the implications of my data, it is important to note that preliminary 
studies were performed in order to identify the most promising gene target/ miRNA pairs 
and narrow the scopes of my studies. To validate that TGFβ signaling was actually being 
affected in MS patients, we analyzed the levels of TGFβR1, TGFβR2, SMAD2, and 
SMAD4 in the naïve CD4 T cells of MS patients and healthy donors. These studies 
demonstrated that TGFβR1 and SMAD4 were the only genes that were significantly 
reduced in MS patients (Figure 3.2). Therefore, we focused my project on the miRNAs 
predicted to target these genes. However, we should not dismiss TGFβR2 completely, as 
it trended towards a decrease in MS patients (Figure 3.2). Additionally, several of the 
miRNAs predicted to target TGFβR2 are also predicted to target TGFβR1 and SMAD4. 
Therefore, I think future studies are needed to assess the levels of TGFβR2 in additional 
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patients samples, as well as miRNA-transfected samples.  Notably, SMAD7, a negative 
regulator of the TGFβ signaling pathway, was also excluded from initial analysis as 
another means of narrowing our focus. However, having now established our 
experimental system, I propose that it would be beneficial to investigate the effects of 
SMAD7-targeting miRNAs on Treg development, allowing us to further enhance our 
knowledge of the extent to which miRNAs regulate the TGFβ signaling pathway and 
affect T cell differentiation.  
 
Taken together, my in vitro data suggest that enhanced levels of the TGFβ-targeting 
miRNAs identified in the naïve CD4 T cells of MS patients decrease capacity to generate 
Tregs and potentially enhance susceptibility to developing MS. When using suboptimal 
Treg inducing conditions, I was able to demonstrate a reduction in the percent of MS and 
miRNA transfected naïve CD4 T cells that were able to differentiate into iTregs, 
appearing to indicate a defect in Treg number (Figure 4.1 and 4.2). Although there has 
been some controversy as to whether MS patients have a reduced number of Tregs, the 
majority of studies suggest that the defect is not in number but in function
 
(Vandenbark, 
Finn et al. 2001, Viglietta, Baecher-Allan et al. 2004, Haas, Hug et al. 2005, Huan, 
Culbertson et al. 2005, Kumar, Putzki et al. 2006, Haas, Fritzsching et al. 2007). 
Therefore, my data is seemingly contradictory to these findings. Interestingly, mice with 
TGFβ deficiencies have normal Treg numbers as adults, however the number of Tregs 
postnatally is significantly reduced (Marie, Letterio et al. 2005, Liu, Zhang et al. 2008, 
Ouyang, Beckett et al. 2010). This limited pool of Tregs, which are CD25+, proliferate in 
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response to IL-2 in the periphery, resulting in normal numbers of Tregs. While normal in 
number, this expanded pool of Tregs has a diminished capacity to suppress effector T 
cells as evidenced by the uncontrolled autoimmunity observed in mice with deficiencies 
in TGFβ signaling (Gorelik and Flavell 2000, Marie, Letterio et al. 2005, Liu, Zhang et 
al. 2008). The inability of Tregs from TGFβ signaling-impaired mice to suppress 
autoimmunity has been attributed to decreased Foxp3 expression and a decreased 
repertoire of Tregs. Similarly, MS patients have also been found to have a decreased TCR 
repertoire in their Tregs (Haas, Fritzsching et al. 2007), indicating that they may have 
insufficient diversity to respond to self-antigens and prevent autoimmunity. In addition, 
thymic output of Tregs was shown to be reduced in pediatric and adult MS patients, and 
differences in suppressive capacity of Tregs in MS patients and controls were dependent 
on the number of new thymic emigrant Tregs, not total number of Tregs (Haas, 
Fritzsching et al. 2007, Balint, Haas et al. 2013). Taking into account these studies, I 
postulate that the reduced frequency of Tregs generated from naïve CD4 T cells of MS 
patients and miRNA transfected samples represent a defect in TCR diversity not number, 
thus mimicking early events in the Treg development of both MS patients and mice with 
TGFβ signaling deficiencies.  Therefore, my data suggests that the miRNAs identified in 
this study may limit Treg development, resulting in the generation of a less diverse 
population of Tregs with diminished suppressive capacity, but capable of expanding in 
response to IL-2. Importantly, my in vitro findings provide a novel link between 
dysregulation of miRNAs, disruption of TGFβ signaling, and suppression of Treg 
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development; providing a foundation for addressing whether these defects can be 
replicated in vivo and cause enhanced susceptibility to developing MS. 
 
To this end, my in vivo findings provide evidence that early dysregulation of TGFβ-
targeting miRNAs may result in defective Treg development and enhanced disease 
susceptibility, in the context of EAE. In attempt to most closely mimic what we believe 
to be occurring in MS patients, I injected neonatal mice within 24 hr of birth with 
miRNA combinations that are commonly observed in MS patients. Ex vivo analysis of 
thymic and splenic Tregs was performed four days after injection with the intention of 
detecting differences in Treg numbers prior to their expansion in response to peripheral 
IL-2. Taken together, my data indicate a reduction of Treg numbers in mice injected with 
the TGFβ-targeting miRNAs (Figure 5.3). However, this observed decrease in Treg 
numbers was not statistically significant. I attribute this lack of consistency to the natural 
fluctuation of Treg numbers between litters. I attempted to randomize the injection 
conditions within individual litters, however maternal rejection was high. My only option 
was to perform timed pregnancies and mix pups from several litters prior to injection. 
Therefore, further experimentation using single litters and an alternative form of pup 
labeling is needed to determine if Treg development is significantly reduced in the 
miRNA-injected mice. I hypothesize that when the miRNA conditions are randomized 
among littermates, we will find that both the development of nTregs and the capacity to 
generate iTregs are significantly inhibited in the miRNA-injected mice. Additionally, 
while outside the scope of my graduate work, I postulate that these mice also have less 
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diverse TCR repertoires, resulting in reduced capacity to recognize the myelin-reactive T 
cells responsible for driving EAE.  In order to address whether overexpression of TGFβ-
targeting miRNAs could also enhance disease susceptibility, EAE was induced in mice 
that received postnatal miRNA injections. My EAE data indicate that overexpression of 
TGFβ-targeting miRNAs results in earlier onset and enhanced severity of disease (Figure 
5.2). Taking into account both my in vitro and in vivo findings, I propose that 
dysregulation of the TGFβ-targeting miRNAs in these mice is causing Treg defects, 
which result in a lack of regulation responsible for the expedited onset and enhanced 
progression of disease. My findings support the hypothesis that the differential expression 
of TGFβ-targeting miRNAs could potentially be used as susceptibility markers for MS.  
 
Taken together, my data support further investigation of the identified miRNAs as 
potential biomarkers. However, there are several factors to take into account. In of 
themselves, miRNAs posses several qualities that make them desirable biomarkers, such 
as their accessibility, relatively low number, and successful application in other immune-
related diseases. However, I do not want to use the term biomarker loosely and 
prematurely label the identified miRNAs as such. Simply stated biomarkers are 
characteristics that can be objectively measured as an indicator of biological processes, 
pathogenic mechanisms, and therapeutic responses (Group. 2001). However, several pre-
clinical and clinical validation steps after the initial discovery of candidate markers are 
needed to truly label something as a “biomarker.” Two of the most challenging but also 
most essential features of a good clinical biomarker are specificity and sensitivity. The 
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identification of a single biomarker capable of both is challenging, especially in multi-
factorial diseases such as MS. For example, some of the healthy controls analyzed in the 
initial miRNA profiling study demonstrated expression levels of single miRNAs similar 
to MS patients, suggesting elevated levels of these individual miRNAs may not be good 
indicators of susceptibility. Interestingly, in contrast to healthy individuals, MS patients 
typically had several of these miRNAs overexpressed, suggesting a potential role for 
panels of miRNAs in the identification of individuals predisposed to developing MS. 
While my data highlight two combinations of miRNAs commonly found in MS patients, 
additional studies using larger cohorts of patients and more in depth analysis of miRNA 
patterns would be required to identify such a panel. These types of studies are outside the 
scope of my graduate research, however my data supports further investigation of 
miRNA combinations as potential indicators of MS risk. Additionally, it is important to 
note that while my observations have been made in the context of MS, it is possible that 
patients with other immune-mediated diseases associated with Treg defects may also 
differentially express TGFβ-targeting miRNAs. To ensure sensitivity of these miRNAs as 
biomarkers for MS, it is necessary to compare their expression levels between MS 
patients and patients with other immune-related diseases. If individuals with other 
immunologic diseases are found to have differential expression of these miRNAs, these 
miRNAs would not be exclusively indicative of MS susceptibility. However, they could 
still serve as predictive markers for therapeutic response, active markers for treatment 
efficacy, or even therapeutic targets. 
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Although my investigation of the identified TGFβ-targeting miRNAs has focused on 
implications in Treg development, it is important to note that TGFβ is a pleiotropic 
cytokine that has potent immunologic effects other than promoting Treg 
differentiation and function.  Therefore, my findings may have broader implications on 
CD4 T cell development and differentiation. For instance, TGFβ has been shown to 
promote the development of Th17 cells in the presence of IL-6 in mice (Bettelli, Carrier 
et al. 2006, Mangan, Harrington et al. 2006, Veldhoen, Hocking et al. 2006), suggesting 
that diminished TGFβ signaling may negatively modulate Th17 cells. However, in the 
case of encephalitogenic T cells, members of the lab and others have found that myelin-
specific Th17 cells differentiated with IL-6 and TGFβ are not encephalitogenic (Yang, 
Weiner et al. 2009, Ghoreschi, Laurence et al. 2010, Lee, Yang et al. 2015). In fact, 
TGFβ is a negative regulator of T-bet, a key transcription factor in encephalitogenic T 
cells, irrespective of whether it has a Th1 or Th17 phenotype (Gocke, Cravens et al. 
2007, Yang, Liu et al. 2010, Lee, Yang et al. 2015). Thus, suppression of the TGFβ 
pathway enhances T-bet expression, as well as promotes the differentiation of pathogenic 
Th17 cells, suggesting that miRNAs that suppress TGFβ signaling may promote the 
development of autoreactive effector T cells. Furthermore, differentiation of human Th17 
cells occurs independently of TGFβ (Acosta-Rodriguez, Napolitani et al. 2007, Wilson, 
Boniface et al. 2007), and TGFβ induces IL-10 expression in autoreactive Th1 cells, 
promoting a self-regulation mechanism (Huss, Winger et al. 2010). IL-10 production has 
been shown to be impaired in MS patients (Cao, Goods et al. 2015), but positively 
associated with therapeutic benefit (Miller, Shapiro et al. 1998, Rudick, Ransohoff et al. 
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1998, Kim, Ifergan et al. 2004).  Thus, diminished TGFβ signaling would potentially 
allow encephalitogenic Th1 cells to mediate pathology more robustly due to a lack of 
inherent regulation. Additionally, I hypothesize that therapeutic benefits associated with 
TGFβ induced IL-10 may be reduced in patients with overexpression of TGFβ-targeting 
miRNAs, suggesting a potential role for these miRNAs as predictive indicators of 
therapeutic response. 
 
In addition to providing novel insight into the Treg defect observed in MS patients, my 
findings also shed some light on past studies as well. Given its immunosuppressive 
properties, TGFβ was used as a successful therapy to ameliorate EAE (Racke, Dhib-
Jalbut et al. 1991). Consequently a clinical trial using TGFβ as a therapy for MS patients 
was performed, but failed (Calabresi, Fields et al. 1998). Taking into account my 
findings, I believe that the dysregulation of miRNAs targeting TGFβR1 and SMAD4 in 
CD4 T cells of MS patients may make these patients less responsive to TGFβ therapy. 
Therefore, they are not able to respond as robustly to TGFβ therapy as mice with fully 
function TGFβ-signaling pathways. Interestingly, my lab has previously demonstrated 
that systemic administration of small RNAs can have therapeutic benefits in CNS 
autoimmunity (Lovett-Racke, Rocchini et al. 2004, Gocke, Cravens et al. 2007, Yang, 
Liu et al. 2010). This poses the question of whether miRNAs could be targeted in order to 
restore the responsiveness of MS patients to TGFβ. In attempt to answer this question, I 
have started preliminary studies using inhibitors of the TGFβ-targeting miRNAs. In these 
studies, I used MS patient cells and transfected them with miRNA inhibitors in the hopes 
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of restoring their capacity to generate iTregs. It is important to note that the cells used 
were from the same MS patients as the initial miRNA profiling study. This is significant 
because I was able to individualize the miRNA inhibitor combinations used based on 
each patient’s miRNA profile. However, I was only able to restore the Treg induction in 
1/5 patients. Opposite to what I expected, 4/5 patients actually exhibited decreased Treg 
development in response to miRNA inhibitors. Given that these miRNAs have the 
capacity to regulate critical genes outside of the TGFβ signaling pathway, therapeutically 
targeting miRNAs may cause unforeseen side effects. While directly targeting these 
miRNAs may not be the best therapeutic approach, I think my findings still support that 
alternative forms of enhancing TGFβ-signaling may result in more robust Treg 
development and provide therapeutic benefits. 
 
While my research has facilitated a better understanding of the lack of regulation 
observed in MS patients by providing a novel link between miRNA-driven inhibition of 
TGFβ signaling and defective Treg development, my findings also opened to the door for 
additional questions and potential implications. One question not readily answered by my 
project is whether miRNA dysregulation can also affect Treg function. My working 
hypothesis is that Tregs generated from naïve CD4 T cells overexpressing the TGFβ-
targeting miRNA will be completely functional, however they will lack the TCR 
diversity need to recognize and suppress myelin-reactive T effector cells. While outside 
the scope of my graduate work, I propose that dissecting the TCR repertoires of patients 
with MS and mice with dysregulated TGFβ-targeting miRNAs could provide a critical 
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link between the miRNA-mediated TGFβ deficiencies and Treg defects in MS patients. 
Another question remaining is the extent to which the Treg defects observed in vivo are 
caused by the differential expression of TGFβ-targeting miRNAs. In the EAE 
experiments, it is unclear whether the miRNA-induced effects on disease onset and 
severity are directly linked to defective Treg development.  Similarly, we have not 
established if the Treg defect observed in MS patients is a direct effect of the 
dysregulation of TGFβ-targeting miRNAs in these individuals. For both the EAE and MS 
studies, correlation analyses need to be performed comparing miRNA levels to Treg 
defects. If Treg defects are shown to correlate with miRNA levels, additional analysis can 
be done to compare Treg defects and disease severity in mice with EAE. A similar study 
in MS patients would be challenging and require significant additional information such 
as the disease status (i.e. phase of disease) of the patients at the time of blood draw. 
Despite these unanswered questions, I have provided the lab with the foundation 
necessary for immediate investigation of these questions, as well as opened the door to 
the potential long-term application of these miRNAs as markers of susceptibility, 
treatment efficacy, and treatment response.  
 
While my observations have been made in the context of CNS autoimmunity, my project 
positively impacts the science community as a whole by providing new insight into how 
miRNAs regulate TGFβ-signaling. Given that TGFβ-signaling is essential for both 
normal and pathogenic processes, my findings may have broader implications on CD4 T 
cell development and differentiation than those observed in MS. Additionally, it is well 
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established that miRNAs play key roles in the development and function of Tregs 
(Dooley, Linterman et al. 2013, Josefowicz 2013), and differential expression of 
miRNAs have been found in MS patients (Du, Liu et al. 2009, Keller, Leidinger et al. 
2009, Otaegui, Baranzini et al. 2009, De Santis, Ferracin et al. 2010, Guerau-de-
Arellano, Smith et al. 2011, Guerau-de-Arellano, Alder et al. 2012, Smith, Guerau-de-
Arellano et al. 2012, Gandhi, Healy et al. 2013, Ridolfi, Fenoglio et al. 2013, 
Søndergaard, Hesse et al. 2013, Keller, Leidinger et al. 2014). Therefore, it is reasonable 
to infer that the TGFβ-targeting miRNAs identified in MS patients may also play a role in 
normal Treg development and function. Notably, none of the miRNAs identified in my 
studies have been previously defined to play a role in normal Treg development. 
Furthermore, MS is not the only disease where Treg regulation is lacking, resulting in 
inappropriate immune responses. Therefore, it is possible that patients with other 
immune-mediated diseases associated with Treg defects may also differentially express 
TGFβ-targeting miRNAs. As such, my findings may have broader implications on the 
maintenance of immune homeostasis. 
 
Overall, my project has led to identification of differentially expressed TGFβ-targeting 
miRNAs in the naïve CD4 T cells of MS patients that can individually or synergistically 
disrupt the TGFβ-signaling pathway, inhibit Treg development, and enhance 
susceptibility to CNS autoimmunity. These findings are of significance as they provide 
novel potential mechanisms for the inherent defects in immune regulation observed in 
MS patients and support my hypothesis that TGFβ-targeting miRNAs may be 
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susceptibility factors for MS. Furthermore, my observations are novel, as no link between 
the disruption of the TGFβ-signaling pathway and the Treg dysfunction in MS patients 
has previously been established. Additionally, the miRNAs identified in my studies have 
not previously been defined to play role in the development of Tregs or CNS 
autoimmunity. Therefore, I believe that the novelty of using miRNAs as a means to 
dissect out differences between MS patients and healthy individuals, provides an 
opportunity to identify candidate biomarkers and therapeutic targets, as miRNAs posses 
characteristics desirable for both. Importantly, the potential clinical application of these 
miRNAs would allow for a novel approach to patient care, allowing for a more 
personalized health plan for patients with MS. 
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